

ANNUAL REPORT 2022

A VITAL LINK
IN HEALTHCARE


PROFILE

Andlauer Healthcare Group Inc. (TSX: AND) is a leading and growing supply chain management company offering a robust platform of customized third-party logistics (“3PL”) and specialized transportation solutions for the healthcare sector. Our 3PL services include customized logistics, distribution and packaging solutions for healthcare manufacturers across Canada. Our specialized transportation services in Canada, including air freight forwarding, ground transportation, dedicated delivery and last mile services, provide a one-stop shop for clients’ healthcare transportation needs. Through our complementary service offerings, available across a coast-to-coast distribution network, we strive to accommodate the full range of our clients’ specialized supply chain needs on an integrated and efficient basis. We also provide specialized ground transportation services, primarily to the healthcare sector, across the 48 contiguous U.S. states.

OPERATIONAL HIGHLIGHTS

- / We provided logistics and distribution, specialized transportation, and packaging solutions to certain of our manufacturer, 3PL provider, wholesaler and government clients that are involved in the Canadian supply of COVID-19 vaccines and ancillary products;
- / We generated year-over-year revenue growth across each of our five product lines;
- / On March 1, 2022, we acquired 100% of the issued and outstanding shares of Logistics Support Unit (LSU) Inc. (“LSU”) for consideration of approximately \$26.7 million. LSU is a third-party logistics provider offering specialty pharmacy, warehousing, distribution and order management services throughout Canada to national and international companies as well as government clients in the pharmaceutical, medical and biotechnology sectors;
- / We successfully integrated LSU, Skelton USA Inc. and T.F. Boyle Transportation, Inc. into the expanding AHG platform; and
- / We continued to maintain service levels across our operations, while monitoring the safety measures implemented in response to COVID-19 to prioritize the health and safety of our personnel, clients, and suppliers.

FINANCIAL PERFORMANCE



(1) Defined as net income (loss) and comprehensive income (loss) for the period before: (i) income tax (recovery) expense; (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization.

(2) The EBITDA, EBITDA Margin and total comprehensive income figures provided above exclude the gain of \$37.9 million on the step acquisition of 51% of Skelton USA Inc. in Fiscal 2021. Including the gain, EBITDA for Fiscal 2021 was \$157.2 million, EBITDA Margin was 35.7%, and total comprehensive income was \$92.8 million.



FELLOW SHAREHOLDERS,



On behalf of our Board of Directors, senior management, and our team of more than 2,200 employees and owner/operators across Canada and the United States, I am pleased to present the Andlauer Healthcare Group (“AHG”) 2022 Annual Report.

Michael Andlauer
Chief Executive Officer

We are proud of our sustained, strong performance. Since our first full year as a public company in 2020, our revenue and net earnings have more than doubled, reflecting our success in delivering value to our customers and capitalizing on growth opportunities. 2022 was excellent year. Our Healthcare Logistics business segment generated 30.7% year-over-year revenue growth in 2022, our Specialized Transportation business segment delivered 54.7% revenue growth, and each of our five product lines contributed to our consolidated revenue growth for the year. Our consolidated EBITDA margin was 26.9% in 2022, which is at the high end of our historical range. Fully diluted earnings per share were \$1.79 compared with \$1.30 last year, excluding the impact of a one-time, non-cash gain.

We have advanced each of the key elements of our growth strategy that were outlined at the time of our initial public offering (“IPO”) and which continue to drive our success. These include strengthening our clients’ connection to our platform by broadening our service offering, increasing our capacity to attract both new clients and new business, pursuing acquisitions to further strengthen our service offering, and our strategic entry into the U.S. market, where we have now established a platform for growth with Boyle Transportation and Skelton USA. During 2022, we commenced development plans for a fifth terminal facility in the U.S. located in the greater Memphis, Tennessee area, to support the growing specialized ground transportation operations of Boyle and Skelton.

In March 2022, we further expanded our Healthcare Logistics segment through the acquisition of Québec-based Logistics Support Unit (“LSU”), a third-party logistics provider offering specialty pharmacy, warehousing, distribution, and order management services throughout Canada. We are currently expanding our operations and capacity in the Montreal area to support continued growth in our Logistics and Distribution product line, with LSU playing a significant role.

These key growth initiatives were executed during a period of significant operational challenges, as the pandemic commenced four months after our IPO. Our strong performance throughout this period demonstrates the dedication and commitment of the entire AHG team to support our customers and underlines the resilient and essential nature of our business.

Letter to Shareholders (continued)

Our leadership team and operating personnel were exemplary in dealing with the pressures and stress of the pandemic environment, while continuing to meet our customer commitments and ensuring the timely delivery of essential products to hospitals, pharmacies and clinics, including the added responsibility of the safe and secure distribution of COVID vaccines and ancillary products. Approximately 3% of our consolidated revenue for 2022 was generated through our ongoing work with manufacturer, third-party logistics, distributor, and government clients involved in the supply of COVID vaccines and related products, compared to approximately 4% in 2021. We expect our COVID vaccine related business activity to continue to decline in 2023.

In addition to the strict adherence to heightened safety measures, additional challenges faced by our team throughout the pandemic included reduced availability of equipment and personnel, and more recently, cost inflation. Fortunately, the pandemic started to ease shortly after the completion of our acquisition of LSU, enabling us to start on the path towards a more normalized operating environment, albeit with continued higher costs. Throughout 2022, our leadership team was highly focused on ensuring the successful integration of Skelton, Boyle and LSU into the AHG platform, while continuing to prioritize the well-being of our employees and drivers. Just as important as the financial contributions and customer benefits of these acquisitions, they have also been an excellent cultural fit, and have seamlessly become a complementary part of the expanding AHG platform.

Supported by our strong and growing free cash flow, we implemented two increases to our quarterly dividend during 2022, increasing our payout from \$0.05 to \$0.07 per share, while also reducing debt and strengthening our balance sheet. Effective for the first quarter of 2023, our Board approved a further increase to our quarterly dividend to \$0.08 per share.

At year end, we had cash and cash equivalents of \$65.9 million, and working capital of \$85 million. This compares to cash and cash equivalents of \$25 million and working capital of \$31.6 million at 2021 year-end. The \$53.5 million increase in working capital is primarily attributable to the increased scale of our business since the acquisitions of LSU, Skelton USA, and Boyle, and the repayment of amounts drawn on our Revolving Credit Facility.

We entered 2023 with solid momentum, a strong balance sheet and multiple opportunities to strengthen our platform through the addition of complementary services or strategic acquisitions. We expect to continue to build on our platform, maintaining our disciplined approach with respect to both financial and operating metrics, and our constant focus on better serving our customers, while also preserving our unique culture of looking after one another. A core value that we will always foster across the AHG platform.

Spending on healthcare logistics and transportation has been outpacing GDP growth in both Canada and the United States, and this trend is expected to continue, supported by favourable demographics, an increasing number of healthcare and adjacent products with unique logistical needs, and continually evolving industry regulation. Further, demand for third-party distribution and ancillary services is increasing as healthcare companies focus more on their core competencies. We are well positioned to capitalize on growth opportunities in this large, stable and growing market to build stakeholder value over the long term.

In closing, I want to thank our Board of Directors for their strategic guidance and governance oversight, and to our dedicated team of people that make up the AHG platform, I extend my sincere appreciation for your essential contributions to our success. And to our shareholders, we appreciate your confidence and continued support. We look forward to the opportunities that lie ahead.

Yours in health,

Michael Andlauer
Chief Executive Officer



ANDLAUER HEALTHCARE GROUP INC.

**Management's Discussion and Analysis
of Financial Condition and Results of Operations
for the fiscal year ended December 31, 2022**

March 2, 2023

TABLE OF CONTENTS

Cautionary Note Regarding Forward-Looking Information	3
Basis of Presentation	5
Non-IFRS Measures	5
Overview	6
Summary of Factors Affecting Performance	7
How We Assess the Performance of Our Business	11
Selected Consolidated Financial Information	15
Reconciliation of Non-IFRS Measures	16
Results of Operations	17
Summary of Quarterly Results	24
Liquidity & Capital Resources	25
Cash Flows	28
Contractual Obligations	29
Off-Balance Sheet Arrangements	30
Seasonality	30
Financial Instruments	30
Related Party Transactions	31
Critical Accounting Judgements and Estimates	34
Significant New Accounting Standards	35
Accounting Classifications and Fair Values	36
Risk Factors	36
Outstanding Share Data	37
Disclosure Controls and Procedures and Internal Controls Over Financial Reporting	38
Additional Information	39

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three months and year ended December 31, 2022 should be read in conjunction with Andlauer Healthcare Group Inc.’s audited annual consolidated financial statements for the fiscal year ended December 31, 2022, along with the related notes thereto. This MD&A is presented as of March 2, 2023 and is current to that date unless otherwise stated.

All references in this MD&A to the “Company”, “AHG”, “us”, “our” or “we” refer to Andlauer Healthcare Group Inc., together with our direct and indirect subsidiaries, on a consolidated basis, which is referred to as “the Company” in our financial statements. Additionally, all references to “Q4 2022” are to the three months ended December 31, 2022; “Q4 2021” are to the three months ended December 31, 2021, “Q3 2022” are to the three months ended September 30, 2022; “Q3 2021” are to the three months ended September 30, 2021; “Q2 2022” are to the three months ended June 30, 2022; “Q2 2021” are to the three months ended June 30, 2021; “Q1 2022” are to the three months ended March 31, 2022; “Q1 2021” are to the three months ended March 31, 2021; “Fiscal 2023” are to the year ending December 31, 2023; “Fiscal 2022” are to the year ended December 31, 2022; “Fiscal 2021” are to the year ended December 31, 2021; and “Fiscal 2020” are to the year ended December 31, 2020.

Cautionary Note Regarding Forward-Looking Information

This MD&A contains forward-looking information and forward-looking statements (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, dividend policy, plans, objectives, acquisition-date fair values of customer relationships and expectations with respect to the coronavirus disease (“COVID-19”) pandemic. Particularly, information regarding our expectations of future results, performance, achievements, facility expansions, leases, platform expansions, acquisitions, public company costs, payment of dividends, prospects, financial targets or outlook, intentions, opportunities, the markets in which we operate and the potential impact of, and response measures to be taken with respect to, COVID-19, including expectations with respect to the distribution of COVID-19 vaccines and ancillary products, is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “does not anticipate”, “believes”, “commencing” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company.

This forward-looking information and other forward-looking information is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this MD&A, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to:

- the impact of inflation and rising interest rates together with the threats of stagflation or recession;
- the uncertainties in the global economy created by the war in Ukraine;
- the impact of variation in the value of the Canadian dollar in relation to the U.S. dollar;
- the impact of changing conditions in the healthcare logistics and transportation services market;
- the impact of the COVID-19 pandemic on our operations, business and financial results;
- risks and liabilities associated with the transportation of dangerous goods;
- our ability to comply with U.S. foreign ownership, control or influence mitigation measures;
- our ability to execute our growth strategies;
- increasing competition in the healthcare logistics and transportation services market in which we operate;
- volatility in financial markets;
- changes in the attitudes, financial condition and demand of our target market;
- developments and changes in applicable laws and regulations;
- our ability to source and complete acquisitions;
- our ability to successfully integrate businesses and assets that we acquire and realize synergies;
- our ability to retain and grow revenue with existing clients and develop new clientele;
- our ability to retain members of our management team and key personnel;
- increases in driver compensation and the ability to attract and retain employees;
- our ability to expand into additional markets; and
- such other factors discussed in greater detail under “Risk Factors” in this MD&A and in our Annual Information Form dated March 2, 2023 for Fiscal 2022 (the “AIF”) which is available on our profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. The opinions, estimates or assumptions referred to above and described in greater detail in “Risk Factors” should be considered carefully by prospective investors.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and allowing investors and others to get a better understanding of our anticipated financial position, results of operations and operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, investors should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this MD&A represents our expectations as of the date of this MD&A (or as of the date they are otherwise stated to be made), and are subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this MD&A is expressly qualified by the foregoing cautionary statements.

Basis of Presentation

Our consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and are presented in thousands of Canadian dollars unless otherwise indicated.

Non-IFRS Measures

This MD&A makes reference to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non-IFRS measures including “EBITDA” and “EBITDA Margin”. These non-IFRS measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Our management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and to determine components of management compensation.

For a description of how we define these non-IFRS Measures and an explanation of why the non-IFRS measures provide useful information to investors, please see “How We Assess the Performance of Our Business – Non-IFRS Measures” below.

For quantitative reconciliations of net income to EBITDA for Q4 2022, Fiscal 2022, Q4 2021, Fiscal 2021 and Fiscal 2020, please see “Reconciliation of Non-IFRS Measures” below.

Overview

AHG was incorporated under the *Business Corporations Act* (Ontario) on November 12, 2019 with its head office located at 100 Vaughan Valley Blvd, Woodbridge, ON, L4H 3C5. The Company's subordinate voting shares ("Subordinate Voting Shares") are listed on the Toronto Stock Exchange (the "TSX") under the stock symbol "AND".

We are a leading and growing supply chain management company with a platform of customized third-party logistics ("3PL") and specialized transportation solutions for the healthcare sector. We offer services to healthcare manufacturers, wholesalers, distributors and 3PL providers, among others, through a comprehensive platform of high quality, technology-enabled supply chain solutions for a range of products, including: pharmaceuticals, vaccines, biologics, blood products, narcotics, precursors, active pharmaceutical ingredients, over-the-counter, natural health, animal health, consumer health, cosmetics, health and beauty aids, and medical devices. We integrate our uniquely designed Canada-wide network of facilities, vehicles, personnel and technology systems into our clients' businesses to offer holistic solutions that span all of our clients' shipping needs and satisfy the requirements of the highly regulated Canadian healthcare sector. During Fiscal 2021, we expanded our specialized transportation capabilities, through acquisitions, into truckload services for the healthcare sector in the United States.

We differentiate our service offerings and deliver value to our clients through our competitive strengths in temperature management, quality assurance and regulatory compliance, technology-enabled visibility throughout the supply chain and security. We are committed to developing and expanding long-term strategic relationships with our clients to provide improved operational efficiencies and access to value-added services. We generate revenue across five principal product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery.

We believe that we are Canada's only national third-party service provider focused exclusively on delivering customized, end-to-end logistics and specialized transportation solutions to the healthcare sector. Our 3PL services are provided under our Accuristix and LSU brands, through which we provide customized logistics, distribution and packaging solutions to various healthcare manufacturers. Our specialized transportation solutions are offered under our ATS Healthcare, ATS Dedicated and Skelton brands in Canada, where we provide a one-stop shop for our clients' healthcare transportation needs through our specialized air freight forwarding, ground transportation, dedicated delivery and last mile services. We believe we are a national leader in the Canadian healthcare logistics and specialized transportation markets we serve.

We also provide specialized transportation services domestically in the United States under our Boyle Transportation and Skelton USA brands (each as defined below). Boyle Transportation provides specialized transportation services to clients in the life sciences (approximately 75-80% of revenue) and government/defense sectors (approximately 20-25% of revenue). Boyle Transportation adheres to stringent quality and security standards, employs highly trained and dedicated professionals, continually invests in advanced technology and equipment, and has an expansive reach across the United States. Skelton USA was launched in 2017 and has been growing rapidly by successfully leveraging its Canadian reputation and brand for expertise in cold chain services. Skelton USA currently serves customers across the United States.

In our healthcare logistics segment, we serve as an extension of our manufacturing clients, leveraging our infrastructure and expertise to manage their supply chain activities, allowing them to focus on other strategic priorities such as sales, marketing, research and development. We focus on serving our logistics clients as comprehensively as possible and incorporate multiple services from all of our related product lines into our customized logistics solutions.

In our specialized transportation segment, we leverage our national infrastructure in Canada to offer coast-to-coast delivery, including specialized facilities, multiple modes of transportation and flexible capacity to accommodate the full range of our clients' logistics and/or transportation needs on an integrated and efficient basis. By combining multiple service offerings, we can effectively provide managed and monitored movement of our clients' temperature sensitive and valuable products through a closed-loop nation-wide system.

Our competitive strengths in temperature management, quality assurance and regulatory compliance, visibility throughout the supply chain and security are deployed across our Canada-wide network of 31 secure, temperature-controlled facilities, the six third-party owned cross-docks that we operate from and by our team of highly-trained employees. Our security, information and monitoring systems, as well as our temperature management expertise, allow us to meet and exceed Health Canada guidelines and regulations, ensuring the integrity and quality of our clients' temperature sensitive healthcare goods and data.

We also have four facilities in the United States.

Additional information about AHG, including our AIF, can be found on our profile on SEDAR at www.sedar.com or on our website at www.andlauerhealthcare.com.

Summary of Factors Affecting Performance

We believe that our performance and future success depend on a number of factors that present significant opportunities for us. These factors are also subject to a number of inherent risks and challenges, some of which are discussed below and in the "Risk Factors" section of this MD&A and in our AIF.

Service Offering

We believe that offering a platform of services designed specifically for the healthcare sector puts us in a unique position as a provider of supply chain solutions. Our competitive strengths in temperature management, quality assurance and regulatory compliance, visibility throughout the supply chain and security allow us to provide healthcare clients with specialized, integrated, end-to-end supply chain solutions. Through our five principal, complementary service offerings: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery, we accommodate our clients' specialized supply chain needs on an integrated and efficient basis.

Relationships with Manufacturers and Distributors

We believe that our market position is strengthened by the desire of our clients to increasingly outsource their supply-chain management to specialized service providers with the healthcare quality systems, operational expertise and experience to efficiently optimize their product distribution. We are committed to developing and expanding long-term strategic relationships with our clients to provide improved operational efficiencies and access to value-added services. From manufacturers to distributors to retail locations to front doors across Canada and the United States, we store, transport and monitor and manage the temperature conditions of a range of healthcare products. Our trained personnel comply with healthcare industry regulations and best practices.

New Development Projects

We secure client contract wins as a foundation for growth and then add incremental warehousing and distribution square footage through capital efficient leases. Given the required lead-time to build and license facilities, as we secure new major client contracts, we typically strategically invest in excess capacity in anticipation of growing client needs, as well as new client opportunities, which enables capital efficient growth.

Demographics and Healthcare Spending

We believe that we are strategically positioned to directly benefit from the strong growth expected in the North American healthcare sector, which is driven by a number of favourable trends including an aging population, increased life expectancy, increasing healthcare spending, and an increasing number of healthcare products requiring unique logistics needs. Vaccines and biologics, for example, are generally temperature sensitive and require varying degrees of temperature conditions for transportation and storage.

Regulatory Environment

In order to maintain the safety, quality and efficacy of healthcare products, government regulations set out rules relating to, among other things, the packaging, warehousing, distribution, transportation and temperature monitoring of such products. The pace of introduction and complexity of such regulations has increased in recent years, including through the introduction of, and revisions to, many Health Canada guidelines, such as Health Canada's GUI-0069 - Guidelines for Environmental Control of Drugs During Storage and Transportation ("GUI-0069"), among others. Recognizing the ever-changing regulatory demands on the healthcare sector, we take a proactive approach to stay aligned with regulatory protocols, provide environments that are compliant with Good Manufacturing Practices and offer our clients' real-time monitoring and reporting. By outsourcing their logistics and transportation needs to AHG and our specialized services platform, our clients can focus on their core business.

While we believe the United States does not have as rigorous standards as Canada or Europe regarding the transportation of healthcare products, healthcare manufacturers are demanding high quality temperature control and monitoring as well as security and visibility for their truckload shipments in the United States, which aligns with our specialized transportation solutions. Both Boyle Transportation and Skelton USA comply with United States Pharmacopeia (USP) chapter <1079> Good Storage & Distribution Practices for Drug Products, to the extent applicable for transportation.

Boyle Transportation complies with U.S. Federal Motor Carrier Safety Administration regulations regarding the transportation of hazardous materials. Additionally, the National Industrial Security Program Operating Manual requires that Boyle Transportation be effectively insulated from any Foreign Ownership, Control, or Influence to perform on certain U.S. Department of Defense contracts and operates, under AHG's ownership, pursuant to a pending Special Security Agreement with the U.S. Defense Counterintelligence and Surveillance Agency.

Competition

We believe that we offer a unique set of services in the marketplace and stand apart from other outsourced healthcare service providers and traditional logistics and transportation companies. In particular, we believe our differentiated capabilities, including our temperature management expertise, together with our coast-to-coast distribution network in Canada and multiple service offerings, uniquely positions us within our industry and sets us apart from companies specializing in global integration and supply chain management, national non-temperature managed solutions, regional temperature managed solutions as well as niche service providers and insourced transportation services. Notwithstanding the foregoing, we do compete with

UPS Supply Chain Solutions, Kuehne + Nagel and Lynden Logistics in our delivery of 3PL services, and with UPS, FedEx, Purolator, and several regional players in the specialized transportation space in Canada.

In the United States, Boyle Transportation and Skelton USA compete with a large number of regional carriers as well as national transportation providers, such as FedEx.

Acquisitions

We selectively evaluate strategically compelling acquisition opportunities that leverage or expand our differentiated capabilities. In pursuing potential acquisition opportunities, we assess several criteria to expand our domestic platform, including: (i) complementary tuck-ins; and (ii) entry or expansion into growth verticals, new verticals and new service offerings. We will continue to assess opportunities for expansion in the U.S. or into international markets through existing platforms that align with our core capabilities and existing service offerings.

In Q4 2020, we completed two tuck-in acquisitions: TDS Logistics Ltd. (“TDS”), now branded as “ATS Dedicated”, and McAllister Courier Inc. (“MCI”), our first acquisitions as a public company. These two regionally focused temperature-controlled transportation businesses increased the reach of our services and expanded our market presence in Ontario.

On March 1, 2021, we acquired 100% of Skelton Canada Inc. (“Skelton”) and 49% of Skelton USA Inc. (“Skelton USA” and together with Skelton, the “Skelton Companies”) which enhanced our platform with expanded national 2-8°C specialized temperature-controlled capabilities and provided us with a strategic entry into the U.S. market.

On November 1, 2021, we acquired 100% of T.F. Boyle Transportation, Inc. (“Boyle Transportation”), which provides specialized transportation services to clients in the life sciences and government/defense sectors, and the remaining 51% of Skelton USA, increasing our aggregate ownership of Skelton USA to 100%.

On March 1, 2022, we acquired 100% of Logistics Support Unit (LSU) Inc. (“LSU”). LSU is a third-party logistics provider offering specialty pharmacy, warehousing, distribution, and order management services throughout Canada to national and international companies as well as government clients in the pharmaceutical, medical, and biotechnology sectors.

Management & Employees

Our employee culture is one of our fundamental strengths and a strategic priority. Our employees are passionate about our business and are dedicated to creating and improving solutions for our clients. We empower our employees through training and professional development programs and maintain open lines of communication that encourage our employees to suggest ways in which we can improve our operations. We recognize and celebrate employees who act as leaders within our team and promote movement within our organization in an effort to retain and encourage our top talent. As a result of this collaborative employee culture, we have fostered strong relationships with our employees across our operating segments, none of which are subject to collective bargaining agreements.

Cost Management

In order to provide the services that we offer, we incur various operating costs. These costs include amongst others, labour, rent, fuel, equipment, and insurance. We are susceptible to increases in the price of these items, many of which can fluctuate, often due to factors beyond our control, such as regional and global supply and demand dynamics, political events, global pandemics, terrorist activities, the strength of the Canadian dollar relative to other currencies, and natural disasters.

To mitigate the risk of cost escalation, we focus on operational excellence, synergies between our product lines and cost controls. We rely on, among other things, long-term planning, budgeting processes, and internal benchmarking to achieve our profitability targets. Additionally, we mitigate the risk of inflation by utilizing leases to finance our network of facilities, many of our vehicles and our logistics equipment, as well as by using third-party service providers. We also mitigate our exposure to rising fuel costs through the implementation of fuel surcharge programs, which pass the majority of cost increases to our clients. In addition, we have implemented a number of policies that focus on asset efficiency, including fuel economy, asset utilization, proper repairs and maintenance of equipment, and measured equipment lease renewals. Many of our contracts include cost escalation indexes that provide for annual price adjustments which further protect us from escalating costs.

Financial and Operational Highlights

We refer the reader to the section entitled “How We Assess the Performance of Our Business” of this MD&A for the definition of the items discussed below and, when applicable, to the section entitled “Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income to EBITDA.

Q4 2022 Compared to Q4 2021

Select highlights include the following:

- Revenue increased 24.6% to \$165.8 million, compared to \$133.0 million in Q4 2021;
- Operating income increased 31.3% to \$28.2 million, compared to \$21.5 million in Q4 2021;
- Net income was \$19.8 million in Q4 2022, compared to \$53.1 million, or \$15.2 million excluding the one-time, non-cash gain of \$37.9 million on the step acquisition of the Company’s equity-accounted investee, Skelton USA (the “gain on step acquisition”), in Q4 2021;
- Total comprehensive income for Q4 2022 was \$17.1 million compared to \$56.0 million, or \$18.1 million excluding the gain on step acquisition in Q4 2021;
- EBITDA was \$44.7 million in Q4 2022 compared to \$73.7 million, or \$35.8 million excluding the gain on step acquisition in Q4 2021;
- EBITDA Margin was 27.0% in Q4 2022, compared to 55.4%, or 26.9% excluding the gain on step acquisition in Q4 2021; and
- During Q4 2022, we continued to provide logistics and distribution, specialized transportation, and packaging solutions to certain of our manufacturer, 3PL provider, wholesaler and government clients that are involved in the Canadian supply of COVID-19 vaccines and ancillary products. In Q4 2022, our COVID-19 vaccine-related revenue comprised approximately 2.3% of total revenue compared with approximately 5.2% in Q4 2021.

Fiscal 2022 Compared to Fiscal 2021

Select highlights include the following:

- Revenue increased 47.3% to \$648.4 million, compared to \$440.1 million in Fiscal 2021;
- Operating income increased 49.7% to \$110.3 million, compared to \$73.7 million in Fiscal 2021;
- Net income was \$76.3 million in Fiscal 2022, compared to \$90.0 million, or \$52.0 million excluding the gain on step acquisition, in Fiscal 2021;
- Total comprehensive income was \$91.0 million in Fiscal 2022, compared with \$92.8 million, or \$54.9 million excluding the gain on step acquisition, in Fiscal 2021;
- EBITDA was \$174.5 million in Fiscal 2022, compared to \$157.2 million, or \$119.3 million excluding the gain on step acquisition, in Fiscal 2021;
- EBITDA Margin was 26.9% in Fiscal 2022, compared to 35.7%, or 27.1% excluding the gain on step acquisition, in Fiscal 2021;
- During Fiscal 2022, approximately 3.0% of total revenue was derived from our clients that are involved in the Canadian supply of COVID-19 vaccines compared with approximately 4.0% in Fiscal 2021; and
- On March 1, 2022, we acquired 100% of the issued and outstanding shares of LSU for consideration of approximately \$26.7 million. LSU is a third-party logistics provider offering specialty pharmacy, warehousing, distribution and order management services throughout Canada to national and international companies as well as government clients in the pharmaceutical, medical and biotechnology sectors. We financed the acquisition through the issuance of 154,639 Subordinate Voting Shares and cash of approximately \$19.2 million. We financed the cash portion of the purchase price through a combination of cash on hand and by drawing on our Credit Facilities (as defined below).

How We Assess the Performance of Our Business

We have historically operated and managed our healthcare logistics and specialized transportation segments as separate businesses with separate management teams. Our healthcare logistics segment operates under the brand names Accuristix and LSU; and our specialized transportation segment operates under the brand names ATS Healthcare, ATS Dedicated, Boyle Transportation and Skelton Truck Lines. Following our initial public offering (“IPO”) completed December 11, 2019, both Accuristix and ATS Healthcare have continued to operate autonomously, each having its own management. Skelton, which we acquired on March 1, 2021, and Boyle Transportation and Skelton USA, which we acquired on November 1, 2021, which are reported in the specialized transportation segment, also operate autonomously, as they did prior to their respective acquisitions. Similarly, LSU, which we acquired on March 1, 2022, operates autonomously and is included in our healthcare logistics segment. Over time, as we grow, our operating segments may change. If this occurs, we will reflect the change in our reporting practices.

Except for tractors and trailers purchased by Skelton and Boyle Transportation, our operating segments conduct their businesses in a manner that limits capital investments. We prefer to lease facilities and certain equipment rather than allocating significant cash flows to capital expenditures. We believe our business model provides us with greater flexibility, cost savings and lower risks, as compared to more capital expenditure intensive models. Accordingly, lease costs comprise a significant component of our expenses. Under IFRS 16 – Leases, leases have been capitalized, resulting in the costs associated with our leases being recorded as depreciation and interest expense. We believe that the cash flows associated with our lease payments are a relevant metric in evaluating the performance of our business.

Revenue

We generate revenue from the provision of supply chain solutions to the Canadian and United States healthcare sectors. Across our healthcare logistics and specialized transportation operating segments, we generate revenue across five principal product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery.

Our healthcare logistics segment, which offers services under our Accuristix and LSU brands, generates revenue from the provision of logistics and distribution services and packaging solutions to our clients. Services are typically provided under master service agreements with terms that range from three to five years in length. Our logistics contracts typically include a single performance obligation that is satisfied over time as clients simultaneously receive and consume the benefits of our services. For this performance obligation, we recognize revenue at the invoiced amount since this amount corresponds directly to our performance and the value to the client. In some cases, our agreements include other performance obligations related to managing transportation and other client services which are included in the logistics and distribution product. These services are typically priced at their stand-alone selling prices and are recognized over time as the client simultaneously receives and consumes the benefits of our services. Intersegment revenue generated by Credo Systems Canada Inc. from the sale of thermal packaging containers to ATS Healthcare, as well as intra-segment revenue between Accuristix and Nova Pack Ltd. (“Nova Pack”) is eliminated on consolidation.

Our specialized transportation segment, which offers services under our ATS Healthcare, ATS Dedicated, Boyle Transportation and Skelton Truck Lines brands, generates revenue from the provision of specialized temperature-controlled, as well as non-temperature controlled, ground transportation, air freight forwarding and dedicated and last mile transportation services to our clients. Certain additional services are provided to clients as requested as part of their transportation contracts, such as chain of custody and other incidental services. Transportation revenue is recognized proportionally as a shipment moves from origin to destination and the related costs are recognized as incurred. Performance obligations are short-term, with transit typically taking less than one week. Generally, clients are billed upon shipment of the freight, and remit payment according to approved payment terms. Intersegment revenue generated by ATS Healthcare and Skelton from the provision of transportation services to Accuristix and LSU, on behalf of their logistics clients, is eliminated on consolidation.

As is customary in our industry, most of our client contracts and transportation pricing terms include fuel-surcharge revenue programs or cost recovery mechanisms to mitigate the effect of fuel price increases over base amounts established in the contract. However, these fuel surcharge mechanisms may not capture the entire amount of changes in fuel prices, and there is also a lag between the payment for fuel and collection of surcharge revenue. Increases or decreases in fuel prices increase or reduce the cost of transportation and services, and will accordingly increase or reduce our revenues and may reduce or increase margins for certain product lines.

Cost of Transportation and Services

Our cost of transportation and services expense includes the cost of providing or procuring freight transportation to our clients. The cost of transportation and services for our specialized transportation segment includes: linehaul costs to connect our national network; pick-up and delivery costs paid to brokers, agents, and our drivers; fuel, toll fees and maintenance costs; and inbound and outbound handling costs which are largely comprised of hourly paid dock labour. The cost of transportation and services for our healthcare logistics segment includes purchased transportation services, including fuel surcharges, sourced from carriers. ATS Healthcare is the largest provider of transportation services to Accuristix and LSU, followed by Skelton. Intersegment purchased transportation expense is eliminated on consolidation.

Direct Operating Expenses

Direct operating expenses are both fixed and variable and consist of operating costs related to our facilities (including our distribution centres, branches and the cross-docks that we operate from). Direct operating expenses consist mainly of personnel costs and facility and equipment expenses such as property taxes, utilities, equipment maintenance and repair, costs of materials and supplies, security and insurance expenses. We note that under IFRS 16 the costs associated with our leases are not recognized in our direct operating expenses.

Selling, General and Administrative Expenses

Selling, General and Administrative (“SG&A”) expenses primarily consist of the cost of salaries and benefits for executive and certain administration functions, including information technology, sales and client service, finance and accounting, professional fees, facility costs, legal costs and other expenses related to the corporate infrastructure required to support our business.

Depreciation & Amortization

Depreciation and amortization charges comprise non-cash charges expensed on the statement of income and comprehensive income to spread the purchase price of assets over their useful lives. Within both of our operating segments, we lease facilities and certain equipment rather than allocating significant cash flows to capital expenditures. We believe this approach provides us with greater flexibility and lower risks and results in cost savings as compared to capital expenditure intensive models. Accordingly, lease costs comprise a significant component of our expenses. Under IFRS 16, leases have been capitalized, resulting in depreciation and interest expense rather than direct operating expense.

Operating Income

Operating Income measures the amount of profit derived from our operations after deducting operating expenses such as cost of transportation and services, direct operating expense, SG&A, and depreciation and amortization. We do not typically measure “cost of sales or gross profit” as we are a service business.

Gain on Step Acquisition of Equity-Accounted Investee

We completed our acquisition of Skelton USA in two separate transactions (49% on March 1, 2021 and the remaining 51% on November 1, 2021). In accordance with IFRS 3 – Business Combinations (“IFRS 3”), we re-measured our previously held equity interest in Skelton USA at its estimated fair value on November 1, 2021 resulting in a gain being recognized from the step acquisition.

Share of Profit of Equity-Accounted Investee, Net of Tax

Following the acquisition of a 49% interest in Skelton USA on March 1, 2021, we determined that AHG did not control Skelton USA until the remaining 51% of Skelton USA was acquired on November 1, 2021. Accordingly, between March 1, 2021 and October 31, 2021, we accounted for our investment in Skelton USA using the equity method of accounting. Under the equity method of accounting, an equity investment is initially recorded at cost and is subsequently adjusted to reflect the investor’s share of the net profit or loss of the investee. From November 1, 2021 forward, Skelton USA is consolidated with AHG in accordance with IFRS 10 – Consolidated Financial Statements.

Interest Expense

Interest expense comprises interest charged to the statement of income and comprehensive income primarily in connection with leased facilities and equipment under IFRS 16, and for borrowings under our Credit Facilities.

Interest Income

Interest income comprises interest earned on cash and cash equivalents. In Fiscal 2021, we sub-leased a facility to a third party that had previously been classified as a right-of-use asset. We derecognized the net book value from right-of-use assets and established a net investment sub-lease in connection with this facility. Interest income includes interest generated by this sub-lease.

Other Income/Expense

Other income (expense) comprises income or expenses that do not arise from our main business, such as exchange gains (losses) and gains (losses) resulting from the sale of property, plant and equipment and certain other insignificant sources.

Income Tax Expense/Recovery

Income tax expense (recovery) comprises the amount that we have recognized in the accounting period related to our taxable income. Our effective tax rate is generally close to the statutory rate, but certain differences between income for tax and accounting income are recognized in the deferred income tax provision.

Foreign Currency Translation Adjustment

In preparing our consolidated financial statements, the financial statements of each entity are translated into Canadian dollars. The assets and liabilities of foreign operations are translated to Canadian dollars at exchange rates as at the balance sheet date. Revenues and expenses of foreign operations are translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transaction. Foreign exchange differences are recognized in other comprehensive income and accumulated in equity in accumulated other comprehensive income.

Non-IFRS Measures

EBITDA

We define EBITDA as net income for the period before: (i) income tax expense (recovery); (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization. Net income is the most directly comparable IFRS financial measure disclosed in our financial statements to which EBITDA relates, and a reconciliation with this measure is presented under “Reconciliation of Non-IFRS Measures”.

We believe EBITDA is a useful measure to assess our financial performance because it provides a more relevant picture of operating results by excluding the effects of expenses that are not reflective of our underlying business performance.

In accordance with IFRS 3, when we obtained control of Skelton USA, we re-measured our previously held equity interest in our equity-accounted investee at its estimated fair value on November 1, 2021 resulting in a gain of \$37.9 million being recognized from the step acquisition in Fiscal 2021. For comparative purposes with other periods, we have presented EBITDA and EBITDA Margin excluding the gain on step acquisition in this MD&A for Fiscal 2021.

EBITDA Margin

We define EBITDA Margin as EBITDA divided by revenue. EBITDA Margin represents a measure of our profitability expressed as a percentage of revenue.

We believe EBITDA Margin is a useful measure to assess our financial performance because it helps quantify our ability to convert revenues generated from clients into EBITDA.

Selected Consolidated Financial Information

The following table summarizes our results of operations for the periods indicated. The selected consolidated financial information for Q4 2022, Q4 2021, Fiscal 2022, Fiscal 2021 and Fiscal 2020 has been derived from our consolidated financial statements and the related notes thereto. See “Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income to EBITDA.

Consolidated Statements of Income and Comprehensive Income

(SCAD 000s)	Three Months Ended		Year Ended		
	December 31,		December 31,		
	2022	2021	2022	2021	2020
Revenue					
Logistics & distribution	37,911	29,521	155,575	115,255	96,976
Packaging solutions	3,925	4,351	21,290	20,072	19,380
Healthcare Logistics segment	41,836	33,872	176,865	135,327	116,356
Ground transportation	113,057	85,268	422,236	261,870	177,170
Air freight forwarding	7,549	10,024	34,383	29,214	22,482
Dedicated and last mile delivery	17,354	14,282	66,896	52,260	29,795
Intersegment revenue	(14,024)	(10,421)	(51,957)	(38,556)	(31,463)
Specialized Transportation segment	123,936	99,153	471,558	304,788	197,984
Total revenue	165,772	133,025	648,423	440,115	314,340
Operating expenses					
Cost of transportation and services	86,336	65,708	322,844	201,784	131,392
Direct operating expense	20,989	21,279	102,280	84,861	75,374
Selling, general and administrative	13,826	10,903	48,502	37,051	28,613
Depreciation & amortization	16,455	13,683	64,452	42,716	28,022
	137,606	111,573	538,078	366,412	263,401
Operating income	28,166	21,452	110,345	73,703	50,939
Gain on step acquisition of equity-accounted investee	-	37,921	-	37,921	-
Share of profit of equity-accounted investee, net of tax	-	371	-	2,469	-
Interest expense	(1,867)	(1,565)	(6,858)	(6,219)	(4,595)
Interest income	396	32	599	198	285
Other income (expense)	63	264	(328)	368	(49)
Income tax expense	(6,934)	(5,371)	(27,483)	(18,486)	(8,866)
Net income	19,824	53,104	76,275	89,954	37,714
Other comprehensive income					
Net income	19,824	53,104	76,275	89,954	37,714
Foreign currency translation adjustment	(2,772)	2,889	14,743	2,889	-
Total comprehensive income	17,052	55,993	91,018	92,843	37,714

(\$CAD 000s)	Three Months Ended December 31,		Year Ended December 31,		
	2022	2021	2022	2021	2020
Earnings per share					
Earnings per share – basic	\$ 0.47	\$ 1.29	\$ 1.82	\$ 2.30	\$ 1.00
Earnings per share – diluted	\$ 0.46	\$ 1.26	\$ 1.79	\$ 2.25	\$ 0.98
Select financial metrics¹					
EBITDA ¹	44,684	73,691	174,469	157,177	78,912
EBITDA Margin ¹	27.0%	55.4%	26.9%	35.7%	25.1%
EBITDA ¹ excluding gain on step acquisition	44,684	35,770	174,469	119,256	78,912
EBITDA Margin ¹ excluding gain on step acquisition	27.0%	26.9%	26.9%	27.1%	25.1%

¹ These are non-IFRS financial measures. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on these measures.

Consolidated Balance Sheets

(\$CAD 000s)	As At December 31,		
	2022	2021	2020
Select financial position data			
Total assets	712,460	644,169	252,797
Total non-current liabilities	185,690	201,521	110,394

Consolidated Statements of Changes in Equity

(\$CAD 000s)	Three Months Ended December 31,		Year Ended December 31,		
	2022	2021	2022	2021	2020
Select financial data					
Dividends	2,934	2,083	10,883	7,854	7,929

Reconciliation of Non-IFRS Measures

The following table provides a reconciliation of net income to EBITDA for the periods indicated:

(\$CAD 000s)	Three Months Ended December 31,		Year Ended December 31,		
	2022	2021	2022	2021	2020
Net income	19,824	53,104	76,275	89,954	37,714
Income tax expense	6,934	5,371	27,483	18,486	8,866
Interest expense	1,867	1,565	6,858	6,219	4,595
Interest income	(396)	(32)	(599)	(198)	(285)
Depreciation and amortization	16,455	13,683	64,452	42,716	28,022
EBITDA¹	44,684	73,691	174,469	157,177	78,912
Gain on step acquisition of equity-accounted investee	-	(37,921)	-	(37,921)	-
EBITDA¹ excluding gain on step acquisition	44,684	35,770	174,469	119,256	78,912

¹ This is a non-IFRS financial measure. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on this measure.

Results of Operations

Three months ended December 31, 2022 compared with 2021

The following section provides an overview of our financial performance for Q4 2022 compared to Q4 2021.

Revenue

Revenue for Q4 2022 increased by 24.6% to \$165.8 million, compared with \$133.0 million in Q4 2021. Our LSU, Boyle Transportation and Skelton USA acquisitions accounted for approximately \$17.6 million of the \$32.7 million increase with the remaining growth attributable to organic growth and fuel surcharge revenue as described below. Approximately 2.3% of our consolidated revenue for Q4 2022, compared with approximately 5.2% for Q4 2021, was generated by working with manufacturer, 3PL, distributor, and government clients involved in the supply of vaccines and related products in connection with the COVID-19 pandemic. We expect that revenues relating to COVID-19 vaccines and ancillary products may continue to decrease in Fiscal 2023 and we do not foresee a return to similar levels of activity in this space as that experienced in Fiscal 2021, which may impact the Company's comparative growth in future periods.

Healthcare Logistics Segment

Revenue in our healthcare logistics segment for Q4 2022 was \$41.8 million, an increase of 23.5%, or approximately \$7.9 million, compared with Q4 2021. The increase in revenue for this segment was primarily driven by the factors set out below.

Logistics & Distribution

Logistics and distribution revenue for Q4 2022 was \$37.9 million, an increase of 28.4%, or approximately \$8.4 million, compared with Q4 2021. Approximately \$2.4 million of the increase, net of year-to-date pass-through expenses reclassified as billings to customers of LSU in Q4 2022, is attributable to our acquisition of LSU on March 1, 2022, with the remaining increase comprising organic growth in outbound order handling activities for Accuristix and increases in transportation billings impacted by fuel surcharge programs from carriers, which are passed on to customers.

Packaging Solutions

Packaging revenue for Q4 2022 was \$3.9 million, a decrease of 9.8%, or approximately \$0.4 million, compared with Q4 2021. Our packaging revenue was impacted primarily by lower volume from one of our larger packaging customers due to component material constraints by their suppliers.

Specialized Transportation Segment

Revenue in our specialized transportation segment for Q4 2022 was \$123.9 million, an increase of 25.0%, or approximately \$24.8 million, compared with Q4 2021. Revenue growth in this segment was primarily driven by the factors set out below.

Ground Transportation

Ground transportation revenue for Q4 2022 was \$113.1 million, an increase of 32.6%, or approximately \$27.8 million, compared with Q4 2021. The increase reflects incremental revenue from our Boyle Transportation and Skelton USA acquisitions of approximately \$15.2 million, representing an increase of 17.8%, with the remainder attributable to organic growth and higher fuel costs passed through to customers as a component of our pricing. The acquisitions of Skelton USA and Boyle Transportation were completed on November 1, 2021, and thereby only contributed two months of revenue during Q4 2021.

Air Freight Forwarding

Air freight forwarding revenue for Q4 2022 was \$7.5 million, a decrease of 24.7%, or approximately \$2.5 million, compared with Q4 2021. Air freight forwarding revenue was unusually high in Q4 2021 as our clients attempted to minimize service disruptions in British Columbia arising from weather events that occurred in November 2021, which severed regional road and rail links to Vancouver due to flooding and landslides. Air freight forwarding volumes returned to normal levels during Q1 2022. Decreased revenues in Q4 2022 as compared to Q4 2021 were marginally offset by higher fuel costs passed on to customers as a component of our pricing.

Dedicated and Last Mile Delivery

Dedicated and last mile delivery revenue for Q4 2022 was \$17.4 million, an increase of 21.5%, or approximately \$3.1 million, compared with Q4 2021. Approximately 50% of the increase is attributable to organic growth with the remaining 50% attributable to increases in fuel costs passed on to customers.

Cost of Transportation and Services

Cost of transportation and services for Q4 2022 was \$86.3 million, or 52.1% of revenue, compared with \$65.7 million, or 49.4% of revenue, for Q4 2021. The higher cost of transportation and services is primarily attributable to the impact of the acquisitions of Boyle Transportation and Skelton USA over a full quarter, compared to two months in Q4 2021, and higher fuel costs in line with the increases in revenue related to fuel prices.

Direct Operating Expenses

Direct operating expenses were \$21.0 million, or 12.7% of revenue, compared with \$21.3 million, or 16.0% of revenue, for Q4 2021. Direct operating expenses in Q4 2022 reflect outbound volume growth in AHG's Accuristix logistics and distribution operations, the acquisition of LSU on March 1, 2022, and a year-to-date reclassification of certain pass-through expenses to logistics and distribution billings for LSU in accordance with IFRS 15.

Selling, General and Administrative Expenses

SG&A expenses for Q4 2022 were \$13.8 million, or 8.3% of revenue, compared with \$10.9 million, or 8.2% of revenue, for Q4 2021. The \$2.9 million increase in Q4 2022 is primarily attributable to the impact of our acquisitions of Boyle Transportation and Skelton USA over a full quarter, and LSU.

Depreciation and Amortization

Depreciation and amortization for Q4 2022 was \$16.5 million, an increase of 20.3% compared with \$13.7 million for Q4 2021. The increase is primarily attributable to depreciation and amortization related to our LSU, Boyle Transportation and Skelton USA acquisitions.

Gain on Step Acquisition of Equity-Accounted Investee

We completed our acquisition of Skelton USA in two separate transactions (49% on March 1, 2021 and the remaining 51% on November 1, 2021). In accordance with IFRS 3, we re-measured our previously held equity interest in Skelton USA at its estimated fair value on November 1, 2021, resulting in a gain of \$37.9 million being recognized from the step acquisition in Q4 2021. Skelton USA has been included in the consolidated results of the Company for all of Fiscal 2022.

Share of Profit of Equity-Accounted Investee, Net of Tax

For Q4 2021, our 49% share of total comprehensive income of Skelton USA was \$0.4 million. On November 1, 2021, Skelton USA became a wholly-owned subsidiary and is included in our consolidated results for all of Fiscal 2022.

Interest Expense

Interest expense for Q4 2022 was \$1.9 million compared with \$1.6 million for Q4 2021. Interest expense related to leased facilities and equipment comprises the majority of interest expense; however, \$0.7 million of interest expense for Q4 2022 was incurred in connection with our Credit Facilities, compared with \$0.3 million in Q4 2021.

At this time, we expect to continue to hold debt under the Term Facility (as defined below), which does not have any repayment schedule except as a single repayment at the end of the four-year term and will incur interest expense until maturity on March 1, 2025.

Interest Income

Interest income for Q4 2022 was \$0.4 million and was negligible in Q4 2021. Interest income is generated on our cash and cash equivalents balances and is earned in connection with our sub-lease of a facility to a third party.

Other Income/Expense

Other income was approximately \$0.1 million for Q4 2022, compared with \$0.3 million in Q4 2021. These amounts are immaterial to our overall performance for Q4 2022 and Q4 2021.

Income Tax Expense

Income tax expense for Q4 2022 was \$6.9 million compared with \$5.4 million in Q4 2021. Our effective tax rate is close to the statutory rate of 26.5% for Q4 2022 and Q4 2021 after removing the effect of non-deductible share-based compensation expenses, and (for Q4 2021 only) the inclusion of the share of profit of our equity-accounted investee, net of tax.

Operating Income and Net Income

Operating income for Q4 2022 was \$28.2 million, an increase of \$6.7 million, or 31.3%, compared with \$21.5 million for Q4 2021. Approximately \$1.3 million of the increase is attributable to our acquisitions of LSU, Boyle Transportation and Skelton USA with the remainder attributable to organic growth.

Income before tax for the specialized transportation segment was \$20.3 million for Q4 2022, compared with \$56.3 million, or \$18.4 million excluding the gain on step acquisition, for Q4 2021. The increase, excluding the gain on step acquisition, is primarily attributable to a full quarter contribution from Skelton USA and Boyle Transportation and organic growth across the segment.

Income before tax for the healthcare logistics segment was \$6.0 million for Q4 2022 compared with \$3.2 million for Q4 2021. The increase reflects greater outbound order handling activities in line with our revenue growth for the period and the acquisition of LSU on March 1, 2022.

Net income for Q4 2022 was \$19.8 million compared with \$53.1 million, or \$15.2 million excluding the gain on step acquisition, in Q4 2021. Higher segment net income before eliminations for both our healthcare logistics and specialized transportation operating segments contributed to the increased profit on a consolidated basis when excluding the gain on step acquisition.

Foreign Currency Translation Adjustment

Foreign exchange differences of \$(2.8) million have been recognized in other comprehensive income for Q4 2022 compared with \$2.9 million in Q4 2021. These differences reflect assets and liabilities of Boyle Transportation and Skelton USA which have been translated to Canadian dollars at the exchange rates as at December 31, 2022 and 2021, and revenues and expenses which have been translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transactions.

Total Comprehensive Income

Total comprehensive income attributable to the owners of the Company was \$17.1 million for Q4 2022 compared to \$56.0 million, or \$18.1 million excluding the gain on step acquisition, for Q4 2021. Total comprehensive income differs from net income due to the acquisition of foreign operations (Boyle Transportation and Skelton USA) resulting in foreign currency translation adjustments as described above.

EBITDA

EBITDA for Q4 2022 was \$44.7 million compared with \$73.7 million, or \$35.8 million excluding the gain on step acquisition, for Q4 2021. The increase (when excluding the gain on step acquisition) was due to the factors discussed above and reflects the incremental contributions of our acquisitions and organic growth in both of our operating segments.

EBITDA Margin

EBITDA Margin for Q4 2022 was 27.0%, compared with 55.4%, or 26.9% excluding the gain on step acquisition for Q4 2021. Q4 2022 EBITDA Margin was impacted by several offsetting factors including the effect of increased fuel prices and the elimination of inter-segment transactions. The performance of our two operating segments continues to result in strong and stable EBITDA Margins. The margin profiles of Boyle Transportation and Skelton USA are in line with AHG's consolidated EBITDA range, and LSU achieved a margin consistent with our logistics and distribution product line.

Year ended December 31, 2022 compared with 2021

The following section provides an overview of our financial performance for Fiscal 2022 and Fiscal 2021.

Revenue

Revenue for Fiscal 2022 increased by 47.3% to \$648.4 million compared with \$440.1 million in Fiscal 2021. Revenue attributable to our acquisitions of LSU, Boyle Transportation and Skelton USA accounted for \$151.4 million of the \$208.3 million increase from Fiscal 2021 to Fiscal 2022.

Healthcare Logistics Segment

Revenue in our healthcare logistics segment for Fiscal 2022 was \$176.9 million, an increase of 30.7%, or approximately \$41.5 million, compared with Fiscal 2021. Revenue growth in this segment was primarily driven by the factors set out below.

Logistics & Distribution

Logistics and distribution revenue for Fiscal 2022 was \$155.6 million, an increase of 35.0%, or approximately \$40.3 million, compared with Fiscal 2021. Our acquisition of LSU on March 1, 2022 contributed approximately \$21.3 million of the increase, with the remaining increase attributable to volume growth within our existing client base and rate increases primarily related to transportation billings impacted

by fuel surcharge programs from carriers, which are passed on to customers.

Packaging Solutions

Packaging revenue for Fiscal 2022 was \$21.3 million, an increase of 6.1% or approximately \$1.2 million compared with Fiscal 2021. During Q4 2022, our packaging revenue was impacted by lower volume from one of our larger packaging customers due to component material constraints by their suppliers.

Specialized Transportation Segment

Revenue in our specialized transportation segment for Fiscal 2022 was \$471.6 million, an increase of 54.7%, or approximately \$166.8 million, compared with Fiscal 2021. Revenue growth in this segment was primarily driven by the factors set out below.

Air Freight Forwarding

Air freight forwarding revenue for Fiscal 2022 was \$34.4 million, an increase of 17.7%, or approximately \$5.2 million, compared with Fiscal 2021. The increase is primarily attributable to an approximate 16% volume increase in Fiscal 2022 as compared to Fiscal 2021, with the remainder attributable to fuel-related revenue driven by increased fuel surcharges.

Ground Transportation

Ground transportation revenue for Fiscal 2022 was \$422.2 million, an increase of 61.2%, or approximately \$160.4 million, compared with Fiscal 2021. Approximately \$112.5 million, or 43.0%, of the increase is attributable to our Boyle Transportation and Skelton USA acquisitions. The remaining increase is primarily attributable to fuel-related revenue driven by increased fuel surcharges and organic growth driven by rate increases.

Dedicated and Last Mile Delivery

Dedicated and last mile delivery revenue for Fiscal 2022 was \$66.9 million, an increase of 28.0%, or approximately \$14.6 million, compared with Fiscal 2021. The increase is primarily attributable to expanded routes for existing clients and increases in fuel costs passed on to customers.

Cost of Transportation and Services

Cost of transportation and services for Fiscal 2022 was \$322.8 million, or 50.0% of revenue, compared with \$201.8 million, or 46.0% of revenue, for Fiscal 2021. The increase is primarily attributable to our acquisitions of Boyle Transportation and Skelton USA, which were consolidated for all of Fiscal 2022 versus only two months in Fiscal 2021. The increase in the operating ratio for Fiscal 2022 as compared to Fiscal 2021 is primarily attributable to higher fuel costs for Fiscal 2022 in line with the increase in ground transportation revenue related to fuel for Fiscal 2022.

Direct Operating Expenses

Direct operating expenses for Fiscal 2022 were \$102.3 million, or 15.8% of revenue, compared with \$84.9 million, or 19.3% of revenue, for Fiscal 2021. Approximately \$7.0 million of the \$17.4 million increase is attributable to our LSU acquisition, with the remaining increase attributable to increased volumes of inbound and outbound receiving and shipping volumes at Accuristix. Our specialized transportation acquisitions (Boyle Transportation and Skelton USA) have lower facility-related costs compared to our healthcare logistics segment, which resulted in a lower direct operating expense operating ratio in Fiscal 2022 as compared to Fiscal 2021.

During Fiscal 2021, we qualified for the CEWS program in connection with our packaging operations. A total of \$1.2 million, or 0.3% of revenue, was recognized as a reduction of direct operating expenses for Fiscal 2021 for assistance received from the CEWS program compared to \$nil in Fiscal 2022.

Selling, General and Administrative Expenses

SG&A expenses for Fiscal 2022 were \$48.5 million, or 7.5% of revenue, compared with \$37.1 million, or 8.4% of revenue, for Fiscal 2021. The increase in SG&A expenses is primarily attributable to the acquisitions of LSU, Boyle Transportation and Skelton USA. SG&A expenses for Fiscal 2022 include share-based compensation arrangements of approximately \$1.3 million, or 0.2% of revenue compared to \$1.9 million, or 0.4% of revenue for Fiscal 2021, which contributed to lower SG&A expenses as a percentage of revenue for Fiscal 2022 as compared to Fiscal 2021. These share-based compensation arrangements relate to the initial stock option grants to our directors and senior management team, and deferred share unit grants to our directors, which are intended to provide further alignment with shareholders.

Depreciation and Amortization

Depreciation and amortization for Fiscal 2022 was \$64.5 million, an increase of 50.9%, or \$21.7 million, compared with \$42.7 million for Fiscal 2021. Our acquisitions of LSU, Boyle Transportation and Skelton USA accounted for the increase.

Other Income/Expense

Other expense for Fiscal 2022 was \$0.3 million compared with other income of \$0.3 million for Fiscal 2021. These amounts are immaterial to our overall performance for these periods.

Interest Income

Interest income for Fiscal 2022 was \$0.6 million compared with \$0.2 million for Fiscal 2021. Interest income is generated on our cash and cash equivalents balances and is earned in connection with our sub-lease of a facility to a third party.

Interest Expense

Interest expense for Fiscal 2022 was \$6.9 million compared with \$6.2 million for Fiscal 2021. Interest expense related to leased facilities and equipment comprises the significant majority of interest expense; however, \$2.0 million of interest expense was incurred in Fiscal 2022 in connection with the Credit Facilities which were entered into at the time of our IPO and increased in connection with the acquisition of Skelton, compared to \$1.4 million in Fiscal 2021. At this time, we expect to continue to hold debt under the Term Facility, which does not have any repayment schedule except as a single repayment at the end of the term and will incur interest expense on the Term Facility for the duration of the term which concludes on March 1, 2025.

Income Tax Expense

Income tax expense for Fiscal 2022 was \$27.5 million compared with \$18.5 million for Fiscal 2021. Our effective tax rate is close to the statutory rate of approximately 26.5% for both Fiscal 2022 and Fiscal 2021 after removing the effect of non-deductible share-based compensation expenses, and (for Fiscal 2021 only) the inclusion of the share of profit of our equity-accounted investee, net of tax.

Operating Income and Net Income

Operating income for Fiscal 2022 was \$110.3 million, an increase of \$36.6 million, or 49.7%, compared with \$73.7 million for Fiscal 2021. Approximately \$14.3 million of the increase is attributable to our acquisitions of LSU, Boyle Transportation and Skelton USA, with the remainder attributable to organic growth.

Income before tax for the specialized transportation segment was \$81.4 million for Fiscal 2022, compared with \$95.5 million, or \$57.5 million excluding the gain on step acquisition, for Fiscal 2021. Approximately \$12.8 million of the increase excluding the gain on step acquisition is attributable to our acquisitions of Boyle Transportation and Skelton USA, with the remainder attributable to organic growth.

Income before tax for the healthcare logistics segment was \$22.2 million for Fiscal 2022 compared with \$15.0 million for Fiscal 2021. The increase reflects greater outbound order handling activities in line with our revenue growth for the period and the acquisition of LSU on March 1, 2022.

Net income for Fiscal 2022 was \$76.3 million compared with \$90.0 million, or \$52.0 million excluding the gain on step acquisition, for Fiscal 2021. Higher segment net income before eliminations for both our healthcare logistics and specialized transportation operating segments contributed to the increased profitability on a consolidated basis, when excluding the gain on step acquisition.

Foreign Currency Translation Adjustment

Foreign exchange differences of \$14.7 million have been recognized in other comprehensive income for Fiscal 2022 compared with \$2.9 million for Fiscal 2021. These differences reflect assets and liabilities of Boyle Transportation and Skelton USA which have been translated to Canadian dollars at the exchange rates as at December 31, 2022 and 2021 and revenues and expenses which have been translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transactions.

Total Comprehensive Income

Total comprehensive income attributable to the owners of the Company was \$91.0 million for Fiscal 2022 compared to \$92.8 million for Fiscal 2021, or \$54.9 million excluding the gain on step acquisition, for Fiscal 2021. Total comprehensive income differs from net income due to the acquisition of foreign operations (Boyle Transportation and Skelton USA) resulting in foreign currency translation adjustments as described above.

EBITDA

EBITDA for Fiscal 2022 was \$174.5 million compared with \$157.2 million, or \$119.3 million for Fiscal 2021 excluding the gain on step acquisition, for Fiscal 2021. The increase in EBITDA was due to the factors discussed above and reflects the incremental contributions of our acquisitions and organic growth in both of our operating segments.

EBITDA Margin

EBITDA Margin for Fiscal 2022 was 26.9% compared with 35.7%, or 27.1%, excluding the gain on step acquisition, for Fiscal 2021. Operating leverage was created in both of our operating segments as a result of volume growth, the continued management of our variable costs, and through our strategic acquisitions of LSU, Boyle Transportation and Skelton USA. Fiscal 2021 EBITDA Margin reflects \$2.5 million or approximately 0.6% related to the equity accounting treatment for Skelton USA.

Summary of Quarterly Results

While there is no significant seasonality to our business, our results are impacted by our clients' storage and shipping activities throughout the year as well as the timing of new client implementations or exits.

The table below sets out our results for each of the eight most recently completed quarters (unaudited):

(\$CAD 000s) except per share data	Q4-22	Q3-22	Q2-22	Q1-22	Q4-21	Q3-21	Q2-21	Q1-21
Total revenue	165,772	164,898	169,402	148,351	133,025	104,199	107,125	95,766
Operating income	28,166	27,860	30,157	24,162	21,452	16,796	18,792	16,663
Net income	19,824	18,995	20,985	16,471	53,104	12,188	13,051	11,611
Total comprehensive income	17,052	32,902	27,560	13,504	55,993	12,188	13,051	11,611
EBITDA ¹	44,684	44,072	46,327	39,386	73,691	28,026	29,973	25,487
Earnings per share – basic	\$0.47	\$0.45	\$0.50	\$0.39	\$1.29	\$0.32	\$0.34	\$0.31
Earnings per share - diluted	\$0.46	\$0.44	\$0.49	\$0.39	\$1.26	\$0.31	\$0.33	\$0.30

¹ This is a non-IFRS financial measure. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on this measure.

Generally, revenue has trended upwards through the past eight quarters reflecting both increased shipping volumes from our clients as well as the impact of price increases which are contractually implemented in both of our operating segments annually or as contracts are renegotiated. Our acquisitions in the past eight quarters have driven step change increases in revenue as well. Revenue in Fiscal 2022 reflect increases in fuel prices which are passed on to customers as a component of our pricing. Revenue in Q3 2022 was slightly lower than Q2 2022 revenue as average diesel fuel prices were lower by approximately 7% than in Q2 2022. Average diesel fuel prices increased again from Q3 2022 to Q4 2022 and remained relatively stable in Q4 2022.

Revenue in the most recent four quarters includes the consolidation of LSU, Boyle Transportation and Skelton USA, resulting in approximately \$17.6 million, \$43.4 million, \$40.3 million, and \$32.5 million of acquired revenue for such quarters, respectively. During Fiscal 2022 and Fiscal 2021, we supported the distribution of COVID-19 vaccines and related products, such as test kits and personal protective equipment. Revenue in Q3 2021 was slightly lower than Q2 2021 revenue as activity related to COVID-19 vaccines was higher in Q2 2021. Revenue related to COVID-19 declined as a percentage of our total revenue throughout Fiscal 2022 from approximately 5.5% in Q1 2022 to approximately 2.3% in Q4 2022 and we expect this trend may continue through Fiscal 2023.

Following several quarters which were impacted by the COVID-19 pandemic, shipping volumes in Q1 2021 returned to more normalized pre-pandemic levels with year-over-year increases averaging in the mid-single digit percentages.

Operating income, net income, comprehensive income, and EBITDA have continued to perform consistently with revenue growth over the past eight quarters and have effectively absorbed the IPO and incremental costs associated with being a public company since December 11, 2019.

We completed our acquisition of Skelton USA in two separate transactions (49% on March 1, 2021 and the remaining 51% on November 1, 2021). Accordingly, in accordance with IFRS 3, we re-measured our previously held equity interest in Skelton USA at its estimated fair value on November 1, 2021 resulting in a gain of \$37.9 million being recognized in income from the step acquisition. Net income, total comprehensive income, EBITDA and earnings per share figures for Q4 2021 reflect this gain.

Liquidity & Capital Resources

Overview

Our principal uses of funds are for operating expenses, taxes, interest, capital expenditures, lease payments and dividends. We believe that cash generated from our operations, together with amounts available under our Credit Facilities will be sufficient to meet our future operating expenses, taxes, interest, capital expenditures, lease payments and any dividends that may be declared by our board of directors. However, our ability to fund operating expenses, taxes, interest, capital expenditures and future lease payments will depend on, among other things, our future operating performance, which will be affected by general economic, financial and other factors, including factors beyond our control. See “Accounting Classifications and Fair Values”, “Summary of Factors Affecting Performance” and “Risk Factors” in this MD&A. We review potential acquisitions and investment opportunities in the normal course of our business and may make select acquisitions and investments to implement our growth strategy when suitable opportunities arise.

Our tuck-in acquisitions of TDS and MCI in October 2020 for a purchase price of approximately \$15.9 million in cash were funded from existing cash flow from operations. We financed the acquisitions of Skelton and the initial 49% of Skelton USA in March 2021 through a combination of cash on hand and by drawing \$50.0 million on our Revolving Credit Facility and \$25.0 million on our Term Facility, and by issuing \$25.0 million of Subordinate Voting Shares to the shareholders of Skelton and Skelton USA. During Fiscal 2021, we repaid \$39.0 million of the \$50.0 million initially drawn on our Revolving Credit Facility in connection with the Skelton and Skelton USA acquisitions.

On November 1, 2021, we completed the acquisitions of 100% of Boyle Transportation and the remaining 51% of Skelton USA, increasing our aggregate ownership of Skelton USA to 100%. The aggregate purchase price for the acquisition of Boyle Transportation was approximately US\$83.0 million (\$104.7 million), of which approximately US\$63.0 million was paid in cash and US\$20.0 million was satisfied by issuing 522,116 Subordinate Voting Shares to the shareholders of Boyle Transportation. The aggregate purchase price for the acquisition of the remaining 51% interest in Skelton USA was approximately \$44.8 million, of which \$19.8 million was paid in cash and \$25 million was satisfied by issuing 518,672 Subordinate Voting Shares to the shareholders of Skelton USA. The cash portion of the purchase price for each acquisition was funded through the completion of a bought deal equity offering on October 26, 2021, pursuant to which AHG issued 2.0 million Subordinate Voting Shares from treasury for gross proceeds of \$96.4 million to the Company, with the remaining amounts funded from existing cash flow from operations.

On March 1, 2022, we acquired LSU for approximately \$26.7 million. We satisfied the purchase price through the issuance of 154,639 Subordinate Voting Shares to the shareholders of LSU and cash of approximately \$19.2 million comprising the cash portion of the purchase price net of provisional customary working capital adjustments. We financed the cash portion of the purchase price through a combination of cash on hand and by drawing on our Revolving Credit Facility. During Fiscal 2022, we repaid \$23.0 million of the amounts drawn on our Revolving Credit Facility in connection with the LSU and Skelton acquisitions. As at December 31, 2022, there was \$nil drawn on our Revolving Credit Facility.

Working Capital

The following table presents our working capital position as at December 31, 2022 and 2021:

(\$CAD 000s)	As at December 31,	
	2022	2021
Cash and cash equivalents	65,855	24,990
Trade and other receivables	98,423	90,093
Inventories	3,326	2,331
Prepaid expenses and other	4,416	4,656
Due from related parties	56	108
Revolving credit facility	-	(11,000)
Accounts payable and accrued liabilities	(42,918)	(39,404)
Current portion of lease liabilities	(26,547)	(26,446)
Income taxes payable	(16,313)	(13,679)
Working Capital	86,298	31,649

As at December 31, 2022, we had working capital of \$86.3 million compared with working capital of \$31.6 million as at December 31, 2021. The \$54.6 million increase in working capital is primarily attributable to the increased scale of our business since the acquisitions of LSU, Boyle Transportation and Skelton USA and the repayment of amounts drawn on our Revolving Credit Facility. Although the Revolving Credit Facility does not have any repayment terms, we classify amounts drawn on it in current liabilities as we expect to reduce any amounts drawn within the following twelve months with free cash flow generated from operations. Other working capital amounts reflect the consolidation of our acquisitions.

Credit Facilities

We entered into credit facilities upon closing of our IPO, comprised of a revolving credit facility (the “Revolving Credit Facility”) in the aggregate principal amount of up to \$75.0 million and a term facility (the “Term Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”) in the aggregate principal amount of up to \$25.0 million. On February 19, 2021, in connection with our acquisitions of Skelton and 49% of Skelton USA, we amended our Credit Facilities to increase the amounts available to be drawn under the Revolving Credit Facility and the Term Facility each by \$25.0 million. The amended Credit Facilities comprise a Revolving Credit Facility in the aggregate principal amount of up to \$100.0 million and a Term Facility in the aggregate principal amount of up to \$50.0 million. The remaining terms and conditions of the Credit Facilities remain unchanged, except that they will mature and be due and payable on March 1, 2025. As at December 31, 2022, the aggregate amount outstanding before financing costs under the Credit Facilities was \$50.0 million under the Term Facility and \$nil under the Revolving Credit Facility.

The Revolving Credit Facility is available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. The Term Facility was drawn in a single Canadian dollar advance of \$25.0 million on closing of the IPO by way of prime rate loans and was subsequently converted to bankers’ acceptances and increased by a single Canadian dollar advance of \$25.0 million by way of bankers’ acceptances in connection with the Skelton acquisitions on March 1, 2021.

The Credit Facilities are subject to customary negative covenants and include financial covenants requiring us to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested on a quarterly basis. As at December 31, 2022, we were in compliance with all of the covenants under the Credit Facilities.

In order to support future potential growth through acquisitions, the Credit Facilities also include an accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate principal amount of up to \$100.0 million, such that any amounts drawn under the accordion feature would be in addition to the amounts ordinarily available, subject to the agreement of participating lenders and provided that we are not, or would not, be in default under the Credit Facilities, or in non-compliance with any financial covenants and an event of default does not or would not exist, after giving effect thereto and provided that all representations and warranties are true and correct immediately prior to, and after giving effect to, such increase. As of the date of this MD&A, this accordion feature remains uncommitted.

Capital Expenditures

Capital expenditures for Q4 2022 and Fiscal 2022 were \$11.0 million and \$25.7 million, respectively, compared with \$2.9 million and \$8.0 million for Q4 2021 and Fiscal 2021, respectively, as Skelton and Boyle Transportation invested to support growth and to maintain their fleets. Capital expenditures have historically been funded through cash flows from operations. We have traditionally divided our capital expenditures into two subcategories, capital expenditures (maintenance) and capital expenditures (growth), which are discussed further below.

Skelton and Boyle Transportation have traditionally purchased their fleets, whereas ATS Healthcare and Skelton USA have historically leased their equipment. As our operating segments run autonomously, we expected these entities to continue their past practices, however the Company is now evaluating different lease versus purchase scenarios for its fleets in order to optimize its free cash flow moving forward. Beyond this evaluation, there are no known trends or expected fluctuations in our capital resources, including expected changes in the mix and relative cost of these resources.

Capital Expenditures (Maintenance)

Maintenance capital expenditures refers to capital expenditures necessary for us to sustain our assets in order to continue operating in our current form. We generally seek to maintain our facilities and equipment at a level consistent with the needs of the sector we operate within and ensure that preventative maintenance programs are in place to achieve the performance expected from our facilities and equipment. Outlays for maintenance capital expenditures for Q4 2022 and Fiscal 2022 were \$7.0 million and \$13.3 million, respectively, compared with \$2.2 million and \$4.1 million, respectively, for Q4 2021 and Fiscal 2021. These capital expenditures were funded through cash flows from operations.

Capital Expenditures (Growth)

Growth capital expenditures comprises expenditures on new assets that are intended to grow our productive capacity. These capital expenditures are made to acquire or expand leasehold improvements, transportation and logistics equipment (including pick-up and delivery equipment, warehouse racking, material handling equipment, warehouse automation equipment and specialized logistics equipment such as coolers or vaults, among others), furniture and fixtures, and computer equipment to support new contracts or additional volume from new business. Outlays for growth capital expenditures for Q4 2022 and Fiscal 2022 were \$4.0 million and \$12.4 million, respectively, compared with \$0.7 million and \$3.9 million in Q4 2021 and Fiscal 2021, respectively. Growth capital expenditures can range from \$5.0 million to over \$15.0 million in any given fiscal year, depending on the underlying expansion need. Growth capital expenditures have also historically been funded through cash flows from operations. Growth capital expenditures for Q4 2022 and Fiscal 2022 relate primarily to the purchase of tractors and trailers by Skelton and Boyle Transportation and include approximately \$0.3 million for Q4 2022 and \$1.7 million for Fiscal 2022 related to warehouse equipment for Accuristix. Growth capital expenditures for Q4 2021 and Fiscal 2021 were attributable to the purchase of tractors and trailers by Skelton (with respect to Q4 2021 only) and leasehold improvements, warehouse racking, material handling equipment, and furniture and fixtures related to our healthcare logistics facility in Brampton, Ontario.

In December 2020, we signed an agreement to implement the Tecsys Itopia® platform, a best-in-class healthcare logistics ‘software as a service’ platform, to replace our prior warehouse management system (“WMS”). Tecsys Inc. is an industry-leading supply chain management software company, and its technology stack will provide us with enhanced warehouse management and transportation management capabilities as well as end-to-end analytics and business intelligence. Our first client went live on our new WMS in Q4 2022 and implementations will continue throughout Fiscal 2023. In Fiscal 2022 we capitalized \$1.6 million to intangible assets in connection with our new WMS.

Cash Flows

The following table presents cash flows for the three months and year ended December 31, 2022 and 2021:

(\$CAD 000s)	Three Months Ended December 31,		Year Ended December 31,	
	2022	2021	2022	2021
Cash flows				
Cash from Operating Activities	36,745	28,349	137,128	84,091
Cash (used in) from Financing Activities	(10,110)	75,089	(51,587)	93,889
Cash used in Investing Activities	(10,928)	(93,005)	(45,557)	(183,382)
Effect of foreign currency translation ¹	(535)	244	881	244
Net change in cash	15,172	10,677	40,865	(5,158)
Select cash flow data				
Capital expenditures	(11,023)	(2,898)	(25,748)	(8,026)
Total cash outflow for leases	(8,506)	(8,020)	(33,822)	(29,947)

¹ Comprises the effect of differences in exchange rates for U.S. dollar opening balance sheet cash balances on January 1, 2022 versus December 31, 2022 and for November 1, 2021 versus December 31, 2021 for Boyle Transportation and Skelton USA.

Cash Flow Generated From Operating Activities

Cash flow generated from operating activities for Q4 2022 and Fiscal 2022 totaled \$36.7 million and \$137.1 million, respectively, compared with \$28.3 million and \$84.1 million for Q4 2021 and Fiscal 2021, respectively. The increase in cash flows generated from operating activities relates principally to profitable business growth, including profitable growth from acquisitions, reflected in the 46.3% increase in Fiscal 2022 EBITDA, excluding the gain on step acquisition, and normal fluctuations in trade accounts receivable and trade accounts payable.

Cash Flow (Used In) Generated From Financing Activities

Cash flow used in financing activities for Q4 2022 and Fiscal 2022 totaled \$10.1 million and \$51.6 million, respectively, compared with cash flow generated from financing activities of \$75.1 million for Q4 2021 and \$93.9 million for Fiscal 2021. The significant cash generated from financing activities in Fiscal 2021 was primarily attributable to draws on our Credit Facilities in connection with the acquisitions of Skelton and 49% of Skelton USA on March 1, 2021. On March 1, 2022 we made a \$12.0 million draw on our Revolving Credit Facility in connection with the acquisition of LSU. In Fiscal 2022 we repaid \$23.0 million on our Revolving Credit Facility, compared with \$39.0 million repaid in Fiscal 2021. The remaining cash flows used in financing activities in Q4 2022, Fiscal 2022, Q4 2021 and Fiscal 2021 relate principally to ordinary course repayments of lease liabilities. In Q3 2022 and Q1 2022 we increased our quarterly dividend to \$0.07 from \$0.06 and to \$0.06 from \$0.05 per Subordinate Voting Share and Multiple Voting Share, respectively.

Cash Flow Used In Investing Activities

Cash flow used in investing activities for Q4 2022 and Fiscal 2022 totaled \$10.9 million and \$45.6 million, respectively, compared with cash flow used in investing activities of \$93.0 million and \$183.4 million, respectively, for Q4 2021 and Fiscal 2021. These amounts are primarily attributable to our acquisitions of LSU in Q1 2022, and Skelton, Boyle Transportation and Skelton USA in Fiscal 2021 which comprised \$19.3 million and \$174.0 million net of cash acquired, in Fiscal 2022 and Fiscal 2021, respectively. The remaining amounts comprised normal course expenditures on property, plant and equipment and intangible assets.

Contractual Obligations

As at December 31, 2022, we had the following contractual commitments:

- Outstanding letters of guarantee in the amount of \$0.4 million (December 31, 2021 – \$0.4 million);
- Commitments relating to the leasing of fleet equipment, ranging from 72 to 84 months, beginning upon delivery to us of the equipment in Fiscal 2023, for total lease commitments of \$11.4 million (December 31, 2021 – \$8.5 million); and
- Commitments to purchase fleet equipment expected to be delivered during Fiscal 2023 totaling \$10.1 million (December 31, 2021 – \$7.8 million).

Credit facilities

As at December 31, 2022, the aggregate amounts outstanding under the Credit Facilities were \$50.0 million under the Term Facility (December 31, 2021 – \$50.0 million) and \$nil under the Revolving Credit Facility (December 31, 2021 – \$11.0 million) before capitalized financing costs. The Credit Facilities will mature and be due and payable on March 1, 2025.

Leases

We lease buildings and equipment in the operation of our healthcare logistics and specialized transportation operating segments. Building lease terms range from five to 10 years, with many leases including optional extension periods. For Q4 2022, facility lease liabilities are calculated using our incremental borrowing rate of 5.14% (Q4 2021 – 3.74%). Equipment lease terms range from one to seven years. For Q4 2022, equipment lease liabilities are calculated using our incremental borrowing rate of 4.78% (Q4 2021 – 3.14%) for our specialized transportation segment and 5.04% (Q4 2021 – 2.57%) for our healthcare logistics segment.

The following table summarizes our contractual obligations as at December 31, 2022 based on undiscounted cash flows:

(\$CAD 000s)	Total	Less than 1 Year	1-5 Years	More than 5 years
Credit facilities	50,000	-	50,000	-
Lease liabilities	124,726	30,523	81,317	12,886
Equipment purchases and lease commitments	21,497	11,875	9,622	-
Other obligations	108,182	59,231	48,951	-
Total contractual obligations	304,405	101,629	189,890	12,886

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have, or are reasonably expected to have, a current or future material impact on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Seasonality

There is no significant seasonality to our business.

Financial Instruments

Financial assets

Accounts receivable are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when we become a party to the contractual provisions of the instrument.

A financial asset (unless it is an account receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. An account receivable without a significant financing component is initially measured at the transaction price.

Our financial assets are comprised of cash and cash equivalents, accounts receivable, and long-term deposits. On initial recognition, we classify these financial assets as measured at amortized cost, when both of the following conditions are met:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

These financial assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on de-recognition is recognized in profit or loss.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been decreased.

For accounts receivable, we apply a simplified approach in calculating expected credit losses (“ECLs”). Therefore, we do not track changes in credit risk but instead recognize a loss allowance based on lifetime ECLs at each reporting date. We have established a provision matrix that is based on our historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

When an account receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are offset against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss.

Financial liabilities

Our financial liabilities are comprised of accounts payable and accrued liabilities, lease liabilities, income taxes payable and amounts due from related parties. Our financial liabilities are measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on de-recognition is also recognized in profit or loss.

Foreign exchange contracts

The Company, from time to time, uses foreign exchange contracts to manage certain exposures to fluctuations in foreign exchange rates as part of its overall risk management program. Earnings impacts from derivatives used to manage a particular risk are reported as part of other comprehensive income.

There were no foreign exchange contracts in place during Fiscal 2022 or as at December 31, 2022.

Related Party Transactions

Intercompany balances and transactions have been eliminated in our consolidated financial statements for the years ended December 31, 2022 and 2021.

During Fiscal 2022 and Fiscal 2021, we entered into transactions with related parties that were incurred in the normal course of business. Our policy is to conduct all transactions and settle all balances with related parties at market terms and conditions. All outstanding balances with these related parties are measured at amortized cost and are to be settled in cash within two months of the reporting date. None of the balances are secured. No expense has been recognized in the current year or prior year for bad or doubtful debts in respect of amounts owed by related parties.

Certain of our operating units provide services to other operating units outside of their reportable segment. Billings for such services are based on negotiated rates, which approximate fair value, and are reflected as revenues of the billing segment. These rates are adjusted from time to time based on market conditions. Such intersegment revenues and expenses are eliminated in our consolidated results. Michael Andlauer, our Chief Executive Officer (“CEO”), is also our Chief Operating Decision Maker (“CODM”). The CODM regularly reviews financial information at the operating segment level in order to make decisions about resources to be allocated to the segments and to assess their performance. Segment results that are reported to the CODM include items directly attributable to a segment, as well as those that can be allocated on a reasonable basis. We evaluate performance based on the various financial measures of our two operating segments.

The amounts below are expressed in thousands of Canadian dollars, unless otherwise specified.

Andlauer Management Group Inc.

As of the date hereof, Andlauer Management Group Inc. (“AMG”) holds all of the Multiple Voting Shares of the Company (the “Multiple Voting Shares” and, together with the Subordinate Voting Shares, the “Shares”) and 10,200 Subordinate Voting Shares, representing approximately 52.1% of the issued and outstanding Shares and 81.3% of the voting power attached to all of the Shares. AMG is owned and controlled by Michael Andlauer, our CEO and a director of the Company.

We undertake a limited amount of administrative shared services for AMG. We expect to continue to incur and recover such costs in connection with AMG. For Fiscal 2022, we charged AMG \$13 (Fiscal 2021 – \$66) for recovery of shared services costs.

Andlauer Properties and Leasing Inc.

Andlauer Properties and Leasing Inc. (“APLI”) is a subsidiary of AMG and leases certain facilities and logistics and transportation equipment to us. We also lease facilities and logistics and transportation equipment from arm’s length providers. During Fiscal 2022, we paid \$2,301 (Fiscal 2021 - \$2,261) for leases of logistics and transportation equipment; and \$2,163 (Fiscal 2021 - \$1,771) for leases of facilities from APLI. The specific facilities that we lease from APLI are located at: 881 Bell Blvd. W, Belleville, Ontario; 18 Sandbourne Dr., Pontypool, Ontario; 80 – 14th Avenue, Hanover, Ontario; 465 Ofield Road South, Dundas, Ontario; 605 Max Brose Drive, London, Ontario; and 5480 61 Avenue SE, Calgary, Alberta. We expect to continue leasing properties and equipment from APLI. For Fiscal 2022, we charged APLI \$20 (Fiscal 2021 - \$19) for recovery of shared services costs.

9143-5271 Québec Inc.

9143-5271 Québec Inc. is a subsidiary of AMG and leases a facility located at 655 Desserte E. Hwy 13, Laval, Québec to AHG. We also lease facilities from arm’s length providers. During Fiscal 2022, we paid \$1,532 (Fiscal 2021 - \$1,532) for this building. We expect to continue leasing this property. For Fiscal 2022, we charged 9143-5271 Québec Inc. \$32 (Fiscal 2021 - \$31) for recovery of shared services costs.

Ready Staffing Solutions Inc.

Ready Staffing Solutions Inc. (“RSS”), a company owned by Mr. Andlauer’s spouse, provides us with temporary agency employee services – providing hourly dock labour for our handling operations, principally in the Greater Toronto Area. We also purchase temporary agency employee services from arm’s length providers. During Fiscal 2022, we expensed \$6,517 (Fiscal 2021 - \$4,918) for purchases of temporary agency employee services from RSS. We expect to continue purchasing temporary agency services from RSS.

1708998 Ontario Limited (Medical Courier Services)

Medical Courier Services (“MCS”) is a subsidiary owned 80% by AMG and provides transportation services to us, providing extended reach for shipments where we do not have our own facilities or equipment. During Fiscal 2022, we expensed \$147 (Fiscal 2021 - \$188) for deliveries subcontracted to MCS. We expect to continue subcontracting deliveries to MCS. Similarly, in Fiscal 2022 we invoiced MCS for \$173 (Fiscal 2021 - \$360) for transportation services provided to MCS. For Fiscal 2022, we charged MCS \$13 (Fiscal 2021 - \$14) for recovery of shared services costs.

Med Express Ltd.

Med Express Ltd. (“MEL”) is a subsidiary owned 100% by AMG. MEL provides transportation services to AHG, providing extended reach for shipments where we do not have our own facilities or equipment. We purchased \$40 in services during Fiscal 2022 (Fiscal 2021 - \$12). We expect to continue to subcontract deliveries to MEL from time to time.

D.C. Racking & Maintenance Inc. and Logiserv Inc.

D.C. Racking & Maintenance Inc. (“DCR”) and Logiserv Inc. (“Logiserv”) are partially owned by Cameron Joyce, an AHG director. DCR provides warehouse racking installation, maintenance and repairs for our healthcare logistics segment. Logiserv provides us with warehouse racking and racking components as well as warehouse racking installation, maintenance and repairs. We also purchase warehouse racking installation, maintenance and repairs, and warehouse racking and racking components from arm’s length providers. During Fiscal 2022, we purchased \$47 (Fiscal 2021 - \$20) of warehouse racking and racking components from Logiserv. During Fiscal 2022, we expensed \$54 (Fiscal 2021 - \$29) for warehouse racking installation, maintenance and repair services provided by DCR and Logiserv. We expect to continue to purchase warehouse racking installation, maintenance and repair services from DCR and Logiserv.

C-GHBS Inc.

C-GHBS Inc. (“C-GHBS”) is a subsidiary of AMG and provides air travel services to us. We also purchase air travel services from arm’s length providers. During Fiscal 2022, we purchased \$104 (Fiscal 2021 - \$67) from C-GHBS. We expect to continue to purchase air travel services from C-GHBS.

Skelton Truck Lines Inc.

Skelton Truck Lines Inc. (“SKINC”) is a wholly-owned subsidiary of Skelton USA. SKINC provides specialized 2-8°C transportation services to Skelton USA in the United States, and Skelton provides specialized 2-8°C transportation services to SKINC in Canada. For the period from March 1, 2021 to October 31, 2021, AHG purchased \$319 of transportation services from SKINC and invoiced \$1,180 to SKINC. Effective November 1, 2021, we acquired the remaining 51% interest in Skelton USA, at which time SKINC became a wholly-owned subsidiary of the Company.

Key Management Personnel

Our key management personnel, and persons connected with them, are also considered to be related parties for disclosure purposes. Key management personnel are defined as those individuals having authority and responsibility for planning, directing and controlling the activities of the Company and include our CEO, the other four named executive officers comprising key management and the board of directors.

During Fiscal 2022, we recorded \$4,556 (Fiscal 2021 – \$5,171) related to key management personnel salaries and benefits, share-based compensation, and director fees.

Due from/to related parties

The charts below summarize amounts due to or from related parties.

(\$CAD 000s)	As at December 31,	
	2022	2021
Accounts receivable		
Andlauer Properties and Leasing Inc.	15	74
Med Express Ltd.	-	2
1708998 Ontario Limited (Medical Courier Services)	32	32
Trade receivables due from related parties	47	108
Due from related parties		
Andlauer Management Group Inc.	56	16
Former T.F. Boyle Transportation, Inc. shareholders	-	92
Due from related parties	56	108
Total due from related parties	103	216
Accounts payable and accrued liabilities		
Ready Staffing Solutions Inc.	463	343
1708998 Ontario Limited (Medical Courier Services)	18	-
Andlauer Properties and Leasing Inc.	73	302
Andlauer Management Group Inc.	9	-
Logiserv Inc.	12	7
C-GHBS Inc.	12	-
Trade payables due to related parties	587	652
Due to related parties		
Andlauer Properties and Leasing Inc.	342	254
Former Skelton Canada Inc. shareholders	-	1,032
Due to related parties	342	1,286
Total due to related parties	929	1,938

Critical Accounting Judgements and Estimates

The preparation of our consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions about future events. These estimates and the underlying assumptions affect the reported amounts of assets and liabilities, the disclosures about contingent assets and liabilities, and the reported amounts of revenues and expenses and apply equally to both our healthcare logistics segment and our specialized transportation segment. Such estimates include the expected credit losses on accounts receivable, the useful life of long-lived assets, our incremental borrowing rate, valuation of property, plant and equipment, valuation of goodwill and intangible assets, the measurement of identified assets and liabilities acquired in business combinations, share-based compensation arrangements, the provision for income taxes and other provisions and contingencies. These estimates and assumptions are based on management's best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. Actual results could differ from these estimates.

Changes in those estimates and assumptions resulting from changes in the economic environment will be reflected in the consolidated financial statements of future periods. Information about critical judgments, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year have been described in our consolidated financial statements for the years ended December 31, 2022 and 2021. Key estimates and assumptions remain consistent with those disclosed in our consolidated financial statements.

The Company attributes value to the customer relationships maintained by LSU, Boyle Transportation, Skelton USA, and Skelton as well as to the brands of each acquired entity. For the year ended December 31, 2022, the Company recorded intangible assets of \$12.7 million (December 31, 2021 - \$115.2 million) in connection with customer relationships and \$3.2 million (December 31, 2021 - \$37.3 million) in connection with the brands of its acquired entities. The determination of the acquisition-date fair value of the customer relationships required the Company to make significant estimates and assumptions regarding future revenue growth from existing customers, future cost of sales and operating expenses, attrition rates, contributory asset charges and discount rates. The determination of the acquisition-date fair value of brands required the Company to make significant estimates and assumptions regarding future revenue growth applicable to brands, royalty rates, long-term growth rates used to determine terminal value and discount rates. The customer relationships and brands are definite life intangible assets each of which will be amortized over ten years.

The goodwill is principally attributable to the premium of established business operations, each with a strong reputation in healthcare transportation, and the synergies expected to be achieved from integrating LSU, Boyle Transportation, Skelton USA, and Skelton into the Company's existing business. Goodwill arising from the Company's business combinations has been allocated to the healthcare logistics segment in Fiscal 2022 and to the specialized transportation segment in Fiscal 2021.

Significant New Accounting Standards

Adopted During the Year

There were no new standards that became effective for periods beginning on or after January 1, 2022 that had a material impact on our annual consolidated financial statements for Fiscal 2022.

To be Adopted in Future Periods

The following new standards and amendments to standards are not yet effective for the year ended December 31, 2022, and have not been applied in preparing the consolidated financial statements for Fiscal 2022:

Amendments to IAS 1 – Classification of Liabilities as Current or Non-current

On January 23, 2020, the IASB issued amendments to IAS 1 – Presentation of Financial Statements, to clarify the classification of liabilities as current or non-current. The amendments are effective for annual periods beginning on or after January 1, 2023. Early adoption is permitted. For the purposes of non-current classification, the amendments removed the requirement for a right to defer settlement or roll over of a liability for at least twelve months to be unconditional. Instead, such a right must have substance and exist at the end of the reporting period. The extent of the impact of adoption of the amendments has not yet been determined.

Accounting Classifications and Fair Values

Our financial instruments consist of cash and cash equivalents, accounts receivable, deposits, and accounts payable and accrued liabilities. We believe that the carrying amount of each of these items is a reasonable approximation of fair value.

Risk Factors

For a detailed description of risk factors associated with the Company, refer to the “Risk Factors” section of our AIF, which is available on the Company’s profile on SEDAR at www.sedar.com.

Credit Risk

We are exposed to credit risk in the event of non-performance by counterparties in connection with our financial assets, namely cash and cash equivalents, accounts receivable and long-term deposits. We do not typically obtain collateral or other security to support the accounts receivable subject to credit risk but mitigate this risk by performing credit check procedures for new clients and monitoring credit limits for existing clients. Thereby, we deal only with what management believes to be financially sound counterparties and, accordingly, do not anticipate significant loss for non-performance.

The maximum exposure to credit risk for cash and cash equivalents, accounts receivable and long-term deposits approximate the amount recorded on the consolidated balance sheets.

Liquidity Risk

Liquidity risk is the risk that we will encounter difficulty in meeting the obligations associated with our financial liabilities that are settled by delivering cash or another financial asset. Our approach to managing liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to our reputation.

Our exposure to liquidity risk is dependent on the collection of accounts receivable, or raising of funds to meet commitments and sustain operations. We control liquidity risk by management of working capital, cash flows and the availability of borrowing facilities.

We have entered into Credit Facilities with affiliates of RBC, CIBC, and The Bank of Nova Scotia, comprised of a Revolving Credit Facility in the aggregate principal amount of up to \$100.0 million and a Term Facility in the aggregate principal amount of up to \$50.0 million. The Credit Facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. In order to support future potential growth through acquisitions, the Credit Facilities also include an accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate principal amount of up to \$100.0 million, such that any amounts drawn under the accordion feature would be in addition to the amounts ordinarily available, subject to the agreement of participating lenders and provided that we are not, or would not, be in default under the Credit Facilities or in non-compliance with any financial covenants and an event of default does not or would not exist, after giving effect thereto and provided that all representations and warranties are true and correct immediately prior to, and after giving effect to, such increase. As at December 31, 2022, the aggregate amounts outstanding under the Credit Facilities were \$50.0 million under the Term Facility and \$nil under the Revolving Credit Facility before capitalized financing costs. As of the date of this MD&A, this accordion feature remains uncommitted.

Our accounts payable and accrued liabilities are due and payable in the short-term.

Interest Rate Risk

We have a Revolving Credit Facility and Term Facility that each bear interest at a floating rate subject to fluctuations in interest rates. Changes in interest rates can cause fluctuations in interest payments and cash flows. We do not use derivative financial instruments to mitigate the effect of this risk. The Credit Facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. At December 31, 2022, the Credit Facilities comprise bankers' acceptances drawn at an interest rate of 5.9%. Although interest rates have increased during Fiscal 2022 there has been no significant impact on our financial condition or results of operations. There may be further increases in interest rates in the near term as the Governing Council of the Bank of Canada continues to target 2-3% inflation, however we expect that any such increases will not significantly impact our financial condition.

Currency Risk

We enter into foreign currency purchase and sale transactions and have assets and liabilities that are denominated in foreign currencies and thus are exposed to the financial risk of earnings fluctuations arising from changes in foreign exchange rates and the degree of volatility of these rates. We use derivative instruments to reduce our exposure to foreign currency risk only where appropriate. During Fiscal 2022 and as at December 31, 2022 there were no derivative instruments in place.

COVID-19

While our business has not been materially and adversely affected by the COVID-19 pandemic to date, the extent to which COVID-19 (including variant strains and mutations) and its effect on the economy will impact our business in the future remains uncertain and may lead to adverse changes in our cash flows, working capital levels, debt balances, operating results and financial position in the future. At this time, we do not believe there is any immediate risk of significant disruption to our services, however the ultimate duration and magnitude of the impact COVID-19 has had and will have on the economy and our business is not known at this time.

In addition to the other risks that we face, which are detailed in the AIF under the heading "Risk Factors", we have exposure, through our financial assets and liabilities, to the following risks from our use of financial instruments: credit risk, liquidity risk, interest rate risk, and currency risk. Senior management monitors risk levels and reviews risk management activities as they determine to be necessary.

Outstanding Share Data

Our authorized share capital consists of an unlimited number of Subordinate Voting Shares, an unlimited number of Multiple Voting Shares and an unlimited number of preferred shares, issuable in series. As at March 2, 2023, there were 20,074,253 Subordinate Voting Shares issued and outstanding, 21,840,000 Multiple Voting Shares issued and outstanding (each of which is convertible into Subordinate Voting Shares on a one-for-one basis), and no preferred shares issued and outstanding. In addition, as at such date we had 1,073,750 options, each of which can be exercised or settled for one Subordinate Voting Share and 50,907 Deferred Share Units issued and outstanding under our omnibus incentive plan. As of the date hereof, AMG holds all of the Multiple Voting Shares and 10,200 of the Subordinate Voting Shares, representing approximately 52.1% of the issued and outstanding Shares and 81.3% of the voting power attached to all of the Shares.

Subject to financial results, capital requirements, available cash flow, corporate law requirements and any other factors that our board of directors may consider relevant, we expect to declare a quarterly dividend on the Subordinate Voting Shares and Multiple Voting Shares equal to approximately \$0.07 per share on an ongoing basis. Our Q4 2022 dividend, in the amount of \$0.07 per Share, was paid on January 16, 2023 to shareholders of record as at December 31, 2022. Dividends are declared and paid in arrears. The amount and timing of the payment of any dividends are not guaranteed and are subject to the discretion of our board of directors.

Disclosure Controls and Procedures and Internal Controls Over Financial Reporting

In compliance with the provisions of National Instrument 52-109 – *Certification of Disclosure in Issuers' Annual and Interim Filings*, we have filed certificates signed by our CEO and by our Chief Financial Officer (“CFO”) that, among other things, report on:

- their responsibility for establishing and maintaining disclosure controls and procedures (“DC&P”) and internal control over financial reporting (“ICFR”) for the Company; and
- the design and effectiveness of DC&P and the design and effectiveness of ICFR.

Management, including our CEO and CFO, does not expect that the disclosure controls or internal controls over financial reporting of the Company will prevent or detect all errors and all fraud or will be effective under all potential future conditions. A control system is subject to inherent limitations and, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems objectives will be met.

Further, the design of a control system must reflect that there are resource constraints, and the benefits of controls must be considered relative to their costs. Inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by individual acts of some persons, by collusion of two or more people or by management override of the controls. Due to the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. The design of any control system is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential conditions. Projections of any evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Disclosure Controls and Procedures

The CEO and the CFO, have designed DC&P, or have caused them to be designed under their supervision, in order to provide reasonable assurance that:

- material information relating to AHG is made known to the CEO and CFO by others, particularly during the period in which the interim and annual filings are being prepared; and
- information required to be disclosed by AHG in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation.

Internal Controls Over Financial Reporting

The CEO and CFO have also designed ICFR, or have caused them to be designed under their supervision, in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

The control framework used to design our ICFR is based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) on Internal Control – Integrated Framework (2013 framework).

Changes in Internal Controls Over Financial Reporting

No changes were made to our ICFR during Fiscal 2022 that have materially affected, or are reasonably likely to materially affect, our ICFR.

Limitation on Scope of Design

We completed the design of DC&P and ICFR related to LSU in Q4 2022, which is now integrated with our existing healthcare logistics segment's control environment. We completed the design of DC&P and ICFR related to Boyle Transportation and Skelton USA in Q3 2022, which are now integrated with our existing specialized transportation segment's control environment.

Additional Information

Additional information about AHG, including our AIF, can be found on our profile on SEDAR at www.sedar.com or on our website at www.andlauerhealthcare.com.



Consolidated Financial Statements of

**ANDLAUER HEALTHCARE
GROUP INC.**

For the years ended December 31, 2022 and 2021



KPMG LLP
Commerce Place
21 King Street West, Suite 700
Hamilton ON L8P 4W7
Canada
Telephone (905) 523-8200
Fax (905) 523-2222

INDEPENDENT AUDITORS' REPORT

To the Shareholders of Andlauer Healthcare Group Inc.

Opinion

We have audited the consolidated financial statements of Andlauer Healthcare Group Inc. (the "Entity"), which comprise:

- the consolidated balance sheets as at December 31, 2022 and December 31, 2021
- the consolidated statements of income and comprehensive income for the years ended December 31, 2022 and December 31, 2021
- the consolidated statements of changes in equity for the years ended December 31, 2022 and December 31, 2021
- the consolidated statements of cash flow for the years ended December 31, 2022 and December 31, 2021
- and notes to the consolidated financial statements, including a summary of significant accounting policies

(hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at December 31, 2022 and December 31, 2021, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (IASB).

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditors' Responsibilities for the Audit of the Financial Statements" section of our auditors' report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements for the year ended December 31, 2022. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our auditors' report.

Assessment of the fair value of acquired customer relationships and brand

Description of the matter

We draw attention to Note 5 to the consolidated financial statements. The Entity acquired Logistics Support Unit (LSU) Inc. ("LSU"). The Entity accounts for acquired businesses using the acquisition method of accounting by recording assets acquired and liabilities assumed at their respective fair values. As a result of the transaction, the Entity acquired intangible assets consisting of customer relationships of \$12,700 thousand and brand of \$3,200 thousand respectively. The determination of the acquisition-date fair value of the customer relationships required the Entity to make significant estimates and assumptions regarding (1) future revenue growth from existing customers, (2) future cost of sales and operating expenses, (3) forecasted attrition rate, (4) contributory asset charges, and (5) discount rate. The determination of the acquisition-date fair value of brand required the Entity to make significant estimates and assumptions regarding (1) future revenue growth applicable to brands, (2) royalty rate, (3) long-term growth rate used to determine terminal value, and (4) discount rate.

Why the matter is a key audit matter

We identified the assessment of the fair value of acquired customer relationships and brand as a key audit matter. This matter represented an area of significant risk of material misstatement due to the magnitude of the balances and the high degree of estimation uncertainty in determining the fair value of acquired customer relationships and brand. Significant auditor judgment and the involvement of those with specialized skills and knowledge were required in performing and evaluating the results of our procedures. This was due to the sensitivity of the fair value of the customer relationships and brand to minor changes in certain significant estimates.

How the matter was addressed in the audit

The primary procedures we performed to address this key audit matter included the following:

We evaluated the appropriateness of future revenue growth, future cost of sales and operating expenses by comparing to actual historical revenue growth, cost of sales and operating expenses generated by LSU. We considered changes in conditions and events to assess the adjustments or lack of adjustments made in arriving at future revenue growth, future cost of sales and operating expenses.

We involved valuation professionals with specialized skills and knowledge who assisted in:

- evaluating the appropriateness of the forecasted attrition rate by comparing to actual historical customer attrition rates,



- evaluating the appropriateness of the contributory asset charges by comparing to independently developed contributory asset charges using a weighted-average-returns-analysis,
- evaluating the appropriateness of the discount rate by comparing against a discount rate range that was independently developed using publicly available market data for comparable entities based on its relative risk profile, leveragability, and liquidity,
- assessing the appropriateness of the royalty rates by comparing to external industry data, and
- evaluating the appropriateness of the long-term growth rate used to determine the terminal value that was independently developed using industry specific long-term growth rates.

Other Information

Management is responsible for the other information. Other information comprises:

- the information included in Management's Discussion and Analysis filed with the relevant Canadian Securities Commissions.
- the information, other than the financial statements and the auditors' report thereon, included in a document likely to be entitled "Annual Report".

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in Management's Discussion and Analysis filed with the relevant Canadian Securities Commissions as at the date of this auditors' report. If, based on the work that we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditors' report.

We have nothing to report in this regard.

The information, other than the financial statements and the auditors' report thereon, included in a document likely to be entitled "Annual Report" is expected to be made available to us after the date of this auditors' report. If, based on the work we will perform on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards (IFRS), and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Entity to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- Provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the consolidated entity to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.
- Determine, from the matters communicated with those charged with governance, those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our auditors' report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this auditors' report is John J. Pryke

A handwritten signature in black ink that reads 'KPMG LLP'. The signature is written in a cursive, slightly slanted style. Below the signature is a horizontal line that starts under the 'K' and ends under the 'P', with a small upward tick at the end.

Chartered Professional Accountants, Licensed Public Accountants

Hamilton, Canada

March 2, 2023

Andlauer Healthcare Group Inc.

Consolidated Balance Sheets

As at December 31, 2022 and December 31, 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

Assets	Note	December 31, 2022	December 31, 2021
Assets			
Current assets			
Cash and cash equivalents		\$ 65,855	\$ 24,990
Trade and other receivables	6	98,423	90,093
Inventories	7	3,326	2,331
Prepaid expenses and other		4,416	4,656
Due from related parties	21	56	108
		<u>172,076</u>	<u>122,178</u>
Non-current assets			
Long-term deposits and other		997	847
Property, plant and equipment	8	175,880	178,112
Goodwill and intangible assets	9	357,698	335,200
Deferred income taxes	17	5,809	7,832
		<u>540,384</u>	<u>644,169</u>
Total Assets		\$ 712,460	\$ 644,169
Liabilities and Equity			
Current liabilities			
Revolving credit facility	11	\$ -	\$ 11,000
Accounts payable and accrued liabilities	10	42,918	39,404
Current portion of lease liabilities	18	26,547	26,446
Income taxes payable		16,313	13,679
		<u>85,778</u>	<u>90,529</u>
Long-term liabilities			
Lease liabilities	18	87,182	100,517
Deferred income taxes	17	48,609	50,430
Due to related parties	21	342	1,286
Term facility	11	49,557	49,288
		<u>185,690</u>	<u>251,930</u>
Total Liabilities		271,468	292,050
Equity			
Common share capital	13	727,835	719,936
Contributed surplus	15	5,806	4,967
Accumulated other comprehensive income		19,642	4,899
Merger reserve	2	(488,916)	(488,916)
Retained earnings		176,625	111,233
		<u>440,992</u>	<u>352,119</u>
Commitments and contingencies	20		
Total Liabilities and Equity		\$ 712,460	\$ 644,169

See accompanying notes to the consolidated financial statements.

On behalf of the Board:

“Peter Jelley”
Director

“Thomas G. Wellner”
Director

Andlauer Healthcare Group Inc.
Consolidated Statements of Income and Comprehensive Income
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

	Note	December 31, 2022	December 31, 2021
Revenue	16	\$ 648,423	\$ 440,115
Operating Expenses			
Cost of transportation and services		322,844	201,784
Direct operating expenses		102,280	84,861
Selling, general and administrative expenses		48,502	37,051
Depreciation and amortization		64,452	42,716
		<u>538,078</u>	<u>366,412</u>
Operating Income		110,345	73,703
Gain on step acquisition of equity-accounted investee	5	-	37,921
Share of profit of equity-accounted investee, net of tax	5	-	2,469
Interest expense	19	(6,858)	(6,219)
Interest income		599	198
Other (expenses) income		(328)	368
		<u>103,758</u>	<u>108,440</u>
Income before income taxes		103,758	108,440
Current income tax expense	17	29,528	21,381
Deferred income tax recovery	17	(2,045)	(2,895)
		<u>27,483</u>	<u>18,486</u>
Net income		\$ 76,275	\$ 89,954
Net earnings per share			
Basic earnings per share	14	\$ 1.82	\$ 2.30
Diluted earnings per share	14	\$ 1.79	\$ 2.25
Other comprehensive income			
Net income		\$ 76,275	\$ 89,954
Foreign currency translation adjustment		14,743	4,899
Loss on hedge related to business combination	5	-	(2,010)
Other comprehensive income for the year		<u>14,743</u>	<u>2,889</u>
Total comprehensive income for the year		\$ 91,018	\$ 92,843

See accompanying notes to the consolidated financial statements.

Andlauer Healthcare Group Inc.
Consolidated Statements of Changes in Equity
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

	Number of shares (thousands) (note 13)	Share capital (note 13)	Accumulated other compre- hensive income	Merger reserve (note 2)	Contributed surplus (note 15)	Retained earnings	Total equity
Balance at December 31, 2021	41,669	\$ 719,936	\$ 4,899	\$ (488,916)	\$ 4,967	\$ 111,233	\$ 352,119
Net income and comprehensive income for the year	-	-	14,743	-	-	76,275	91,018
Shares issued in connection with business combinations (note 5)	155	7,500	-	-	-	-	7,500
Transaction costs, net of tax (notes 5, 13, 17)	-	(63)	-	-	-	-	(63)
Share-based compensation (note 15)	90	462	-	-	839	-	1,301
Dividends (note 13)	-	-	-	-	-	(10,883)	(10,883)
Balance at December 31, 2022	41,914	\$ 727,835	\$ 19,642	\$ (488,916)	\$ 5,806	\$ 176,625	\$ 440,992
Balance at December 31, 2020	37,603	\$ 549,662	\$ -	\$ (488,916)	\$ 4,448	\$ 29,133	\$ 94,327
Net income and comprehensive income for the year	-	-	2,889	-	-	89,954	92,843
Shares issued in connection with business combinations (note 5)	1,799	75,166	-	-	-	-	75,166
Net shares issued in connection with new issue and secondary offering (note 13)	2,000	96,400	-	-	-	-	96,400
Transaction costs, net of tax (notes 5, 13, 17)	-	(3,285)	-	-	-	-	(3,285)
Share-based compensation (note 15)	267	1,993	-	-	519	-	2,512
Dividends (note 13)	-	-	-	-	-	(7,854)	(7,854)
Transfer of loss on hedge related to business combination (note 5)	-	-	2,010	-	-	-	2,010
Balance at December 31, 2021	41,669	\$ 719,936	\$ 4,899	\$ (488,916)	\$ 4,967	\$ 111,233	\$ 352,119

See accompanying notes to the consolidated financial statements.

Andlauer Healthcare Group Inc.
Consolidated Statements of Cash Flow
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

	Note	December 31, 2022	December 31, 2021
Operating activities			
Net income for the year		\$ 76,275	\$ 89,954
Changes not involving cash:			
Gain on step-acquisition of equity-accounted investee	5	-	(37,921)
Depreciation and amortization		64,452	42,716
Amortization of capitalized financing costs	11	269	242
Share-based compensation	15	1,301	1,861
Share of profit of equity-accounted investee, net of tax	5	-	(2,469)
Deferred income tax recovery	17	(2,045)	(2,895)
Loss on disposal of property, plant and equipment		(48)	(103)
Net gain on derecognition of right-of-use assets	18	-	(142)
		<u>140,204</u>	<u>91,243</u>
Changes in non-cash operating working capital:			
Trade and other receivables		(2,855)	(14,184)
Inventories		(317)	(472)
Accounts payable and accrued liabilities		1,485	4,449
Income taxes payable		(1,716)	3,176
Net change in other operating working capital balances		327	(121)
Cash flows from operating activities		<u>137,128</u>	<u>84,091</u>
Financing activities			
Dividends	13	(10,883)	(7,854)
Principal repayments on lease liabilities	18	(29,034)	(25,109)
Net change in related party balances		(607)	(2,293)
Proceeds from revolving credit facility	11	12,000	50,000
Proceeds from term facility	11	-	25,000
Repayment of revolving credit facility	11	(23,000)	(39,000)
Net financing costs on credit facilities	11	-	(621)
Proceeds from issuance of share capital	13, 15	-	97,051
Transaction costs recorded in share capital	13	(63)	(3,285)
Cash flows (used in) from financing activities		<u>(51,587)</u>	<u>93,889</u>
Investing activities			
Purchase of property, plant and equipment		(25,748)	(8,026)
Proceeds on disposal of property, plant and equipment		1,721	258
Purchase of intangible assets	9	(2,212)	(1,642)
Acquisition of equity accounted investee	5	-	(7,648)
Business combinations, net of cash acquired	5	(19,318)	(166,324)
Cash flows used in investing activities		<u>(45,557)</u>	<u>(183,382)</u>
Net increase (decrease) in cash and cash equivalents		39,984	(5,402)
Effect of foreign currency translation on cash and cash equivalents		881	244
		<u>40,865</u>	<u>(5,158)</u>
Cash and cash equivalents, beginning of year		24,990	30,148
		<u>24,990</u>	<u>30,148</u>
Cash and cash equivalents, end of year		<u>\$ 65,855</u>	<u>\$ 24,990</u>

See accompanying notes to the consolidated financial statements.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

1. Reporting entity

Andlauer Healthcare Group Inc. (“AHG”, or the “Company”) was incorporated under the Ontario Business Corporations Act with its head office located at 100 Vaughan Valley Blvd. in Woodbridge, Ontario. AHG’s subordinate voting shares are listed on the Toronto Stock Exchange under the stock symbol “AND”. AHG specializes in third party logistics and transportation solutions for the healthcare sector in Canada and the United States.

In addition to the shares issued to the public, Andlauer Management Group Inc. (“AMG”) holds 21.84 million multiple voting shares and 10,200 subordinate voting shares of AHG, representing approximately 52.1% of the issued and outstanding shares and 81.3% of the voting power attached to all of the shares. AMG is owned and controlled by Michael Andlauer, Chief Executive Officer, Chief Operating Decision Maker (“CODM”), and a director of AHG.

2. Basis of presentation

a) Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and using the accounting policies described herein.

b) Basis of measurement

These consolidated financial statements were prepared on a going concern basis under the historical cost method except for share based compensation and business combinations, which were recorded at fair value. Significant accounting policies are presented in note 3 to these consolidated financial statements and have been consistently applied in each of the periods presented. Certain comparative figures have been reclassified to conform with the financial statement presentation adopted in the current year. These consolidated financial statements were authorized for issue by the Board of Directors effective March 2, 2023.

Common control transaction

These consolidated financial statements comprise the results of AHG and Associated Logistics Solutions Inc., Credo Canada Systems Inc., 2186940 Ontario Inc., Skelton Canada Inc., and their respective subsidiaries. Prior to the Company’s initial public offering (“IPO”) on December 11, 2019, certain of AHG’s subsidiaries (Associated Logistics Solutions Inc., Credo Canada Systems Inc., 2186940 Ontario Inc. and their respective subsidiaries at that time – collectively, the “AHG Entities”) were owned 100% by AMG. Pursuant to a share purchase agreement between AHG and AMG, and in connection with a corporate reorganization immediately prior to the IPO, AHG acquired a 100% ownership interest in the AHG Entities based on the value of consideration of \$577,625. Total net parent investment immediately prior to the IPO was \$88,709. A merger reserve of \$488,916 is recorded to reflect the difference in carrying value of the net assets acquired and the consideration paid since AHG and the AHG Entities were all related parties under common control of AMG at the time of the acquisition. Business combinations involving entities under common control are outside the scope of IFRS 3 Business Combinations. AHG accounted for this common control transaction using book value accounting, based on the book values recognized in the financial statements of the underlying entities.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

2. Basis of presentation (continued)

c) Basis of consolidation

(i) Business combinations

The Company accounts for acquired businesses using the acquisition method of accounting by recording assets acquired and liabilities assumed at their respective fair values. The Company measures goodwill as the fair value of the consideration transferred including the fair value of liabilities resulting from contingent consideration arrangements, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured at fair value as of the acquisition date.

Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.

(ii) Subsidiaries

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The Company controls an entity when it is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The accounting policies of subsidiaries are aligned with the policies adopted by the Company.

The Company's wholly-owned subsidiaries include:

Entity	Incorporation Jurisdiction
13811361 Canada Inc.	Canada
2040637 Ontario Inc.	Ontario
2186940 Ontario Inc.	Ontario
2721275 Ontario Limited	Ontario
Accuristix Healthcare Logistics Inc.	Ontario
Accuristix Inc.	Canada
Accuristix	Ontario
Associated Logistics Solutions Inc.	Ontario
ATS Andlauer Transportation Services GP Inc.	Canada
ATS Andlauer Transportation Services LP	Manitoba
Boyle Acquireco, Inc. ³	Delaware
Boyle Holdco, Inc. ³	Delaware
Concord Supply Chain Solutions Inc. ¹	Delaware
Credo Systems Canada Inc.	Ontario
Logistics Support Unit (LSU) Inc. ⁴	Canada
McAllister Courier Inc.	Ontario
MEDDS Canada – A Medical Delivery Service Corporation ¹	Canada
MEDDS Winnipeg – A Medical Delivery Service Corporation	Manitoba
Nova Pack Ltd.	Ontario
Skelton Canada Inc. ²	Ontario
Skelton Truck Lines, Inc. ³	Delaware
Skelton U.S.A. Inc. ³	Ontario
T.F. Boyle Transportation, Inc. ³	Massachusetts
TDS Logistics Ltd.	Ontario

¹ Entity has been dormant throughout the entire reporting period.

² Acquired on March 1, 2021. Refer to note 5.

³ Acquired on November 1, 2021. Refer to note 5.

⁴ Acquired on March 1, 2022. Refer to note 5

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

2. Basis of presentation (continued)

c) Basis of consolidation (continued)

(iii) Transactions eliminated on consolidation

Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the consolidated financial statements.

d) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented in Canadian dollars has been rounded to the nearest thousand. The functional currency of Canadian operations is the Canadian dollar and the functional currency of U.S. operations is the U.S. dollar.

e) Judgments and estimates

Preparing the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. In preparing these consolidated financial statements, significant judgments made by management in applying the accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended December 31, 2021. Information about significant judgments, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year are included in the following notes:

- Note 5 – Establishing the fair value of assets and liabilities, intangible assets and goodwill related to business combinations;
- Note 6 – Determining the expected credit losses (“ECLs”) related to trade accounts receivable;
- Note 8 – Estimating the useful life of the Company's property, plant and equipment and determining estimates and assumptions related to impairment tests for long-lived assets;
- Note 9 – Estimating the useful life of the Company's intangible assets and determining estimates and assumptions related to impairment tests for intangibles and goodwill;
- Note 15 – Determining the valuation of share-based compensation arrangements;
- Note 17 – Determining estimates and assumptions in measuring deferred tax assets and liabilities;
- Note 18 – Estimating the Company's incremental borrowing rate in connection with measuring lease liabilities; and
- Note 20 – Recognition and measurement of provisions and contingencies.

3. Significant accounting policies

Foreign currency translation

Transactions in foreign currencies are translated to the respective functional currencies of each entity at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate in effect at the reporting date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated at the rate in effect on the transaction date. Income and expense items denominated in foreign currency are translated at the date of the transactions. Gains and losses are included in income or loss.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Foreign currency translation (continued)

In preparing the Company's consolidated financial statements, the financial statements of each foreign entity are translated into Canadian dollars. The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on business combinations, are translated to Canadian dollars at exchange rates as at the balance sheet date. Revenues and expenses of foreign operations are translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transaction. Foreign exchange differences are recognized in other comprehensive income and accumulated in equity in accumulated other comprehensive income.

If the Company or any of its subsidiaries disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the accumulated foreign currency translation gains or losses related to the foreign operation are recognized in net income.

Revenue

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those products or services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The following is a description of the Company's performance obligations for the transportation and logistics reportable segments.

a) Specialized Transportation

The Company's transportation segment generates revenue from providing specialized ground transportation, air freight forwarding and dedicated and last mile transportation services for its customers. Certain additional services may be provided to customers as part of their transportation contracts, such as temperature control and other incidental services. The transaction price is based on the consideration specified in the customer's contract. A contract exists when a customer under a transportation contract submits a shipment document for the transport of goods from origin to destination. The performance obligations within each contract are satisfied as the shipments move from origin to destination. Transportation revenue is recognized proportionally as a shipment moves from origin to destination and the related costs are recognized as incurred. Performance obligations are short-term, with transit days less than one week. Generally, customers are billed upon shipment of the freight, and remit payment according to approved payment terms.

b) Healthcare Logistics

The Company's healthcare logistics segment generates revenue from providing supply chain services for its customers, including logistics and distribution services and packaging solutions. The Company's contracts typically include a single performance obligation that is satisfied over time as customers simultaneously receive and consume the benefits of the Company's services. For this performance obligation, the Company recognizes revenue at the invoiced amount, which is billed on a fixed price per unit of logistics activities provided in the month, since this amount corresponds directly to the Company's performance and the value to the customer. In some cases, the Company's contracts include other performance obligations related to managing transportation and other customer services which are included in the logistics and distribution of products. These services are typically priced at their stand-alone selling prices and are recognized over time as the customer simultaneously receives and consumes the benefits of the Company's services. The Company acts as an agent on behalf of its customers for a limited number of contracts in which certain products are purchased and sold on a pass-through basis. In such cases, net billings are included in revenue.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Revenue (continued)

b) Healthcare Logistics (continued)

Contracts with customers that contain multiple performance obligations require the Company to allocate the contractual transaction price to the identified distinct performance obligations. The allocation of the transaction price requires management to determine the standalone selling price for each distinct performance obligation. These services are recognized as revenue when they are provided to the customer.

Customers are typically billed on a weekly basis for transactional transportation services, and on a monthly basis for logistics and distribution services, and remit payment according to approved payment terms. Payment terms may range under certain contracts but are typically 30 days. The Company recognizes unbilled revenue for transportation service revenue that has been recognized but is not yet billed. The Company will also recognize deferred revenue when customers are billed in advance for transportation and logistics and distribution services.

Property, plant and equipment

Property, plant and equipment is accounted for at cost less accumulated depreciation and accumulated impairment losses.

Cost includes expenditures that are directly attributable to the acquisition of the asset, the costs of dismantling and removing the assets and restoring the site on which they are located and borrowing costs on qualifying assets.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized in net income or loss.

Depreciation is based on the cost of an asset less its residual value and is recognized in income or loss over the estimated useful life of each component of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term.

Depreciation is computed on either a declining balance basis or a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Amortization Method
Facilities	Straight-line over the term of the lease
Furniture and fixtures	20-30% declining balance
Leasehold improvements	5-15 year straight-line subject to the shorter of remaining lease term or useful life
Logistics and transportation equipment	Primarily 20-30% declining balance, except for storage vaults which are amortized straight line over 40 years, and certain transportation equipment which is amortized straight line over periods of 3-7 years

Property, plant and equipment acquired or constructed during the year but not placed into use during the year are not amortized until put into use.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Goodwill and intangible assets

Recognition and measurement

Goodwill arising on the acquisition of subsidiaries is measured at cost less accumulated impairment losses.

Intangible assets consist of customer relationships, brands, and internally generated software.

Customer relationships and brands that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses.

For internally generated software, expenditure on research activities is recognized in income or loss as incurred. Development expenditure is capitalized only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Otherwise, it is recognized in income or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortization and any accumulated impairment losses.

Amortization

Goodwill is not amortized.

Customer relationships and brands are amortized on a straight-line basis over their estimated useful lives of between 5 and 10 years.

Internally generated software is amortized on a straight-line basis over 10 years. Internally generated software developed during the year but not placed into use during the year is not amortized until placed into use.

Impairment

The carrying amounts of the Company's non-financial assets other than inventoried supplies and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For goodwill, the recoverable amount is estimated on December 31 of each year as part of the annual impairment test. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit", or "CGU").

For the purposes of goodwill impairment testing, goodwill acquired in a business combination is allocated to the group of CGUs (usually an operating segment of the Company), that is expected to benefit from the synergies of the combination. This allocation is subject to an operating segment ceiling test and reflects the lowest level at which that goodwill is monitored for internal reporting purposes. The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or group of assets.

An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses recognized in respect of CGUs are allocated first to reduce the carrying amount of any goodwill allocated to the units, if any, and then to reduce the carrying amounts of the other assets in the unit (group of units) on a prorated basis.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Impairment (continued)

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Impairment losses and impairment reversals are recognized in income or loss.

Leases

At inception of a contract, the Company assesses whether a contract is, or contains a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether:

- The contract involves the use of an identified asset – this may be specified explicitly or implicitly, and should be physically distinct or represents substantially all the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified;
- The Company has the right to obtain substantially all of the economic benefits from use of the asset throughout the period of use; and
- The Company has the right to direct the use of the asset. The Company has the right when it has the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Company has the right to direct the use of the asset if either:
 - the Company has the right to operate the asset; or
 - the Company designed the asset in a way that predetermines how and for what purpose it will be used.

At inception or on reassessment of a contract that contains a lease component, the Company allocates the consideration in the contract to each lease component on the basis of their relative stand-alone prices. For the leases of land and buildings in which it is a lessee, the Company has elected to account for the lease and non-lease components separately.

a) For arrangements in which the Company is a lessee

The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The ROU asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the ROU asset or the end of the lease term. The estimated useful lives of ROU assets are determined by the estimated lease term. In addition, the ROU asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Leases (continued)

a) For arrangements in which the Company is a lessee (continued)

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable under a residual value guarantee; and
- the exercise price under a purchase option that the Company is reasonably certain to exercise, lease payments in an optional renewal period if the Company is reasonably certain to exercise an extension option, and penalties for early termination of a lease unless the Company is reasonably certain not to terminate early.

The lease liability is measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option.

When the lease liability is re-measured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in income or loss if the carrying amount of the right-of-use asset has been reduced to zero.

b) Short-term leases and leases of low-value assets

The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less and leases of low-value assets, including IT equipment. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

c) For arrangements in which the Company is a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease.

To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. As part of this assessment, the Company considers certain indicators such as whether the lease is for the major part of the economic life of the asset.

If an arrangement contains lease and non-lease components, the Company applies IFRS 15 to allocate the consideration in the contract.

The Company recognizes lease payments received under operating leases as income on a straight-line basis over the lease term as part of 'other income'.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Income taxes

Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in income or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable income or loss, and differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future. In addition, deferred tax is not recognized for taxable temporary differences arising on the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable income will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Financial instruments

Financial assets

Trade and other receivables are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when the Company becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is an account receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss ("FVTPL"), transaction costs that are directly attributable to its acquisition or issue. An account receivable without a significant financing component is initially measured at the transaction price.

The Company's financial assets are comprised of cash and cash equivalents, trade and other receivables, due from related parties, and long-term deposits. On initial recognition, the Company classifies these financial assets as measured at amortized cost, when both of the following conditions are met:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

These financial assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in income or loss. Any gain or loss on derecognition is recognized in income or loss.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been decreased.

For accounts receivables, the Company applies a simplified approach in calculating ECLs. Accordingly, the Company does not track changes in credit risk but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

When an account receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are offset against the allowance account. Changes in the carrying amount of the allowance account are recognized in income or loss.

Financial liabilities are classified at amortized cost

The Company's financial liabilities are measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in income or loss. Any gain or loss on derecognition is also recognized in income or loss.

Transaction costs

Transaction costs that are incremental and directly attributable to the acquisition or issue of a financial asset or financial liability are recorded as follows:

- Financial assets or financial liabilities at fair value through profit and loss – expensed to net income as incurred;
- Financial assets or liabilities recorded at amortized cost – included in the carrying value of the financial asset or financial liability and amortized over the expected life of the financial instrument using the effective interest method; and
- Equity instruments recorded at fair value through other comprehensive income – included in the initial cost of the underlying asset.

Derivative contracts and hedge accounting

The Company, from time to time, uses foreign exchange contracts to manage certain exposures to fluctuations in foreign exchange rates as part of its overall risk management program. Earnings impacts from derivatives used to manage a particular risk are reported as part of other comprehensive income.

When the Company enters into a foreign exchange forward contract to manage foreign exchange rate risk in connection with a business combination, the hedge is considered a hedge of a non-financial item and is therefore recognized in other comprehensive income with a corresponding adjustment to goodwill when the business combination occurs.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Inventories

Inventories, which consist of repair parts, materials and supplies, are carried at the lower of cost and net realizable value. Cost is determined on a first-in, first-out basis and includes all costs of purchase and any other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

Provisions

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the unwinding of the discount is recognized as finance cost.

Segmented reporting

The Company is organized into two reportable segments: Specialized Transportation and Healthcare Logistics. In the Specialized Transportation segment, the Company provides specialized temperature controlled services to healthcare customers. The Company's transportation products include: ground transportation (comprising less-than-truckload and courier services), air freight forwarding, and dedicated and last mile delivery.

In the Healthcare Logistics segment, the Company provides contract logistics services for customers, including logistics and distribution (comprising warehousing and inventory management, order fulfillment, reverse logistics, and transportation management), and packaging (comprising reusable thermal packaging solutions and trade customization services).

Certain of the Company's operating units provide services to other Company operating units outside of their reportable segment. Billings for such services are based on negotiated rates, which approximates fair value, and are reflected as revenues of the billing segment. These rates are adjusted from time to time based on market conditions. Such intersegment revenues and expenses are eliminated in the Company's consolidated results. The Company's chief executive officer is the Chief Operating Decision Maker ("CODM") for the Company. The CODM regularly reviews financial information at the reporting segment level in order to make decisions about resources to be allocated to the segments and to assess their performance. Segment results that are reported to the CODM include items directly attributable to a segment, as well as those that can be allocated on a reasonable basis. The Company evaluates performance based on the various financial measures of its two reporting segments.

Andlauer Healthcare Group Inc.

Notes to Consolidated Financial Statements

For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

3. Significant accounting policies (continued)

Share-based compensation

The Company has an omnibus stock option plan and records all stock-based payments, including grants of employee stock options, at their respective fair values. The fair value of stock options granted to employees and directors is estimated at the date of grant using the Black Scholes option pricing model. The Company recognizes share-based compensation expense over the vesting period, over the life of the tranche of shares being considered. The Company also estimates forfeitures at the time of grant and revises its estimate, if necessary, in subsequent periods if actual forfeitures differ from these estimates. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to contributed surplus are credited to share capital. If a cashless exercise is undertaken, the employee or director will surrender a number of options in order to fund the cashless exercise and a further amount, representing the difference between the market price and the exercise price of the shares may be adjusted to share capital unless the Company chooses to sell the shares in the amount required to fund the cashless exercise. The Company's stock option plan is equity-settled.

The Black-Scholes option pricing model used by the Company to calculate option values was developed to estimate the fair value. This model also requires assumptions, including expected option life, volatility, risk-free interest rate and dividend yield, which greatly affect the calculated values.

Expected option life is determined using the time-to-vest-plus-historical-calculation-from-vest-date method that derives the expected life based on a combination of each tranche's time to vest plus the actual or expected life of an award based on the past activity or remaining time to expiry on outstanding awards. Expected forfeiture is derived from historical patterns. Expected volatility is determined using comparable companies for which the information is publicly available, adjusted for factors such as industry, stage of life cycle, size and financial leverage. The risk-free interest rate is determined based on the rate at the time of grant and cancellation for zero-coupon Canadian government securities with a remaining term equal to the expected life of the option. Dividend yield is based on the stock option's exercise price and expected annual dividend rate at the time of grant.

Government assistance

The Company recognizes government assistance when there is reasonable assurance that it will comply with the conditions required to qualify for the assistance, and that the assistance will be received. The Company recognizes government assistance as a reduction to the related expense that the assistance is intended to offset.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

4. Segment reporting

The Company is organized into operating segments, which aggregate into two reportable segments: Specialized Transportation and Healthcare Logistics. The operating segments are managed independently as they require different technology and capital resources. For each of the operating segments, the Company's CODM reviews internal management reports, evaluating the metrics as summarized in the tables that follow.

The Company evaluates performance based on the various financial measures of its operating segments. Performance is measured based on segment income or loss before tax. This measure is included in the internal management reports that are reviewed by the Company's CEO and refers to "Income before income taxes" in the consolidated statements of income and comprehensive income. Segment income or loss before tax is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within the same industries.

The following table identifies selected financial data as at December 31, 2022 and 2021 and for the years then ended:

	Specialized Transportation	Healthcare Logistics	Corporate	Eliminations	Total
As at December 31, 2022 and for the year then ended					
Revenue	\$ 523,515	\$ 176,865	\$ 5,225	\$ (57,182)	\$ 648,423
Segment income before tax	81,352	22,247	159	-	103,758
Interest income	(2,887)	(39)	3,525	-	599
Interest expense	(3,759)	(2,085)	(1,014)	-	(6,858)
Depreciation and amortization	(50,148)	(14,304)	-	-	(64,452)
Segment net income	60,102	16,265	(92)	-	76,275
Segment total assets	554,903	175,528	734,498	(752,469)	712,460
Additions of ROU assets	11,810	228	-	-	12,038
Additions of property, plant and equipment through business combinations ¹	-	5,159	-	-	5,159
Capital expenditures	23,179	2,569	-	-	25,748
Segment total liabilities	236,796	88,868	30,766	(84,962)	271,468
As at December 31, 2021 and for the year then ended					
Revenue	\$ 343,344	\$ 135,327	\$ 3,780	\$ (42,336)	\$ 440,115
Segment income before tax	95,465	14,994	(2,019)	-	108,440
Interest income	(3,233)	122	3,309	-	198
Interest expense	(3,581)	(2,164)	(474)	-	(6,219)
Depreciation and amortization	(30,700)	(12,016)	-	-	(42,716)
Segment net income	80,889	11,031	(1,966)	-	89,954
Segment total assets	524,127	131,754	737,350	(749,062)	644,169
Additions of ROU assets	22,547	11,028	-	-	33,575
Additions of property, plant and equipment through business combinations ¹	54,010	-	-	-	54,010
Capital expenditures	5,410	2,616	-	-	8,026
Segment total liabilities	280,854	68,867	31,382	(89,053)	292,050

¹ Includes \$3,798 for the year ended December 31, 2022 (2021 - \$17,798) of ROU assets acquired through business combinations

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

4. Segment reporting (continued)

The Company's Healthcare Logistics segment purchases transportation services from its Specialized Transportation segment. Fees for these services are based on negotiated rates, which approximate fair value, and are reflected as revenues of the Specialized Transportation segment. Rates are adjusted from time to time based on market conditions. The Company also charges fees for services and costs incurred from its corporate office to subsidiaries. Intersegment revenues and expenses and related intersegment payables and receivables are eliminated in the Company's consolidated results.

The Company does not have any customers that individually represent more than 10% of revenue for the years ended December 31, 2022 and 2021.

5. Business combinations

On March 1, 2022, the Company acquired all of the issued and outstanding shares of Logistics Support Unit (LSU) Inc. ("LSU"), a leading third-party logistics provider offering specialty pharmacy, warehousing, distribution and order management services throughout Canada to national and international companies, as well as government clients in the pharmaceutical, medical and biotechnology sectors, for \$26,747, the estimated fair value of the business acquired. The acquisition was financed through a combination of cash on hand, drawing \$12,000 on the credit facilities and by issuing 154,639 subordinate voting shares totaling \$7,500 to the shareholder of LSU.

On November 1, 2021 the Company acquired 100% of T.F. Boyle Transportation, Inc. ("Boyle") and 51% of Skelton USA Inc. ("Skelton USA"), increasing AHG's aggregate ownership of Skelton USA to 100%. Boyle provides specialized transportation services to clients in the life sciences and government and defense sectors and Skelton USA specializes in the transportation of refrigerated healthcare products domestically in the United States through its wholly-owned subsidiary, Skelton Truck Lines, Inc. The estimated fair value of Boyle was \$104,715 (US \$83,041). The estimated fair value for the remaining 51% of Skelton USA was \$50,000 before purchase consideration was reduced by \$5,237 for certain tax liabilities attributed to the selling shareholders absorbed by the Company. The Company used the net proceeds of the sale of subordinate voting shares by it under a new issue public offering (refer to note 13 and the Company's short form prospectus dated October 19, 2021), together with cash on hand, to pay the aggregate cash purchase price of \$99,312. The remaining purchase price of \$50,166 was settled by the issuance of 1,040,788 subordinate voting shares from treasury.

On March 1, 2021, the Company acquired all of the issued and outstanding shares of Skelton Canada Inc. ("Skelton"), a leading transportation partner to the Canadian pharmaceutical and biologics industry for \$107,306, the estimated fair value of the business acquired. The acquisition was financed through a combination of cash on hand, drawing \$75,000 on the credit facilities and by issuing 757,576 subordinate voting shares totaling \$25,000 to the shareholders of Skelton. As part of the same transaction, the Company acquired a 49% interest in, Skelton USA for cash consideration of \$7,642. Management determined that it did not control Skelton USA until AHG acquired the remaining 51% of Skelton USA on November 1, 2021. Accordingly, between March 1, 2021 and December 31, 2021, the Company accounted for its investment in Skelton USA using the equity method of accounting.

Under the equity method of accounting, an equity investment is initially recorded at cost and is subsequently adjusted to reflect the investor's share of the net income or loss of the associate. The Company's 49% share of total comprehensive income of Skelton USA for the period from March 1, 2021 to October 31, 2021 was \$2,469. The net book value of the Company's 49% interest in Skelton USA at November 1, 2021 was \$10,117.

AHG achieved its acquisition of Skelton USA in two steps (49% on March 1, 2021 and the remaining 51% on November 1, 2021). Accordingly, the Company remeasured its previously held equity interest in Skelton USA at its estimated fair value on November 1, 2021 resulting in a gain of \$37,921 being recognized from the step acquisition.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

5. Business combinations (continued)

For the period from acquisition on March 1, 2022 to December 31, 2022, LSU contributed revenue of \$21,275 and net income before amortization of intangible assets acquired of \$3,390 (\$2,065 net of intangible amortization) to the Company's financial results. If the Company had acquired LSU on January 1, 2022, management estimates that consolidated revenue would have been approximately \$651,800, and consolidated net income would have been approximately \$78,600. In determining these amounts, management has assumed that the fair value adjustments that arose on the dates of acquisition would have been the same had the acquisition occurred on January 1, 2022.

For the period from acquisition on November 1, 2021 to December 31, 2021, Boyle and Skelton USA together contributed revenue of \$19,001 and net income before amortization of intangible assets acquired of \$3,283 (\$1,726 net of intangible amortization). For the period from acquisition on March 1, 2021 to December 31, 2021, Skelton contributed revenue of \$33,562 and net income before amortization of intangible assets acquired of \$5,596 (\$2,336 net of intangible amortization) to the Company's financial results. If the Company had acquired Boyle, Skelton USA, and Skelton on January 1, 2021, management estimates that consolidated revenue would have been approximately \$525,300 and consolidated net income before amortization of intangible assets acquired would have been approximately \$109,000 (\$93,400 net of intangible amortization). In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisitions would have been the same had the acquisition occurred on January 1, 2021.

During the year ended December 31, 2022, transaction costs of \$345 (December 31, 2021 – \$1,809) have been expensed in selling, general and administrative expenses in the consolidated statements of income and comprehensive income and \$63 (2021 – \$104), net of deferred taxes, has been charged to share capital in relation to these acquisitions.

The following table, which has been revised from the provisional amounts included in the Company's consolidated financial statements for the year ended December 31, 2021 in connection with Boyle and Skelton USA, summarizes the acquisition date fair value of identifiable net assets and goodwill acquired:

Identifiable assets acquired and liabilities assumed	LSU (March 1, 2022)	Boyle (November 1, 2021)	Skelton USA (November 1, 2021)	Skelton (March 1, 2021)
Cash and cash equivalents	\$ (71)	\$ 8,261	\$ 1,371	\$ 5,662
Trade and other receivables	4,636	5,344	6,329	4,590
Inventories	663	-	175	451
Prepaid expenses and other	140	156	1,274	274
Property, plant and equipment, including ROU assets	5,159	20,789	5,381	27,840
Intangible assets	15,900	48,730	64,685	39,100
Accounts payable and accrued liabilities	(1,778)	(7,032)	(971)	(1,384)
Income taxes payable	(4,160)	-	(6,634)	(1,005)
Due to related parties	-	-	(3,758)	-
Lease liabilities	(3,398)	(2,994)	(3,277)	(7,121)
Deferred tax liabilities	(2,496)	(16,825)	(16,807)	(13,990)
Total identifiable net assets	14,595	56,429	47,768	54,417
Goodwill	12,152	48,286	45,033	52,889
Net book value of equity-accounted investee	-	-	(10,117)	-
Gain on step acquisition of equity-accounted investee	-	-	(37,921)	-
Total purchase consideration	\$ 26,747	\$ 104,715	\$ 44,763	\$ 107,306

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

5. Business combinations (continued)

The provisional acquisition date fair values of identifiable assets acquired, and liabilities assumed, for Boyle and Skelton USA were finalized during the measurement period. Measurement period adjustments were made to reflect new information obtained by management with respect to facts and circumstances that existed at November 1, 2021, resulting in a reduction of \$1,116 for Boyle and \$1,200 for Skelton USA both to deferred tax liabilities and to goodwill. There were no other revisions to identifiable net assets. Measurement period adjustments were recorded during the year ended December 31, 2022.

Trade and other receivables comprise gross amounts due of \$4,636 (2021 - \$16,263), all of which were expected to be collectible at the acquisition dates.

On October 5, 2021, when management announced definitive agreements to acquire Boyle, the Company entered into a foreign exchange forward contract to manage foreign exchange rate risk related to the Company's net investment in Boyle for which the U.S. dollar is the functional currency. The Company recognized a loss from the hedge of \$2,010 in other comprehensive income and as an adjustment to goodwill on November 1, 2021 when the business combination occurred.

When measuring the fair value of property, plant and equipment, the Company considers market prices for similar items when they are available, and depreciated replacement cost when appropriate. Depreciated replacement cost reflects adjustments for physical deterioration as well as functional and economic obsolescence.

The Company attributes value to the customer relationships maintained by LSU, Boyle, Skelton USA, and Skelton, and to the brands of each acquired entity. For the year ended December 31, 2022, the Company recorded intangible assets of \$12,700 (2021 - \$115,218) in connection with customer relationships and \$3,200 (2021 - \$37,297) in connection with the brands of its acquisitions. The determination of the acquisition-date fair value of the customer relationships required the Company to make significant estimates and assumptions regarding future revenue growth from existing customers, future cost of sales and operating expenses, forecasted attrition rate, contributory asset charges and discount rate. The determination of the acquisition-date fair value of brands required the Company to make significant estimates and assumptions regarding future revenue growth applicable to brands, royalty rate, long-term growth rate used to determine terminal value and discount rate. The customer relationships and brands are definite life intangible assets each of which will be amortized over 10 years.

The goodwill is principally attributable to the premium of established business operations, each with a strong reputation in healthcare logistics or specialized transportation, and the synergies expected to be achieved from integrating LSU, Boyle, Skelton USA, and Skelton into the Company's existing business. Goodwill arising from the Company's business combinations has been allocated to the Healthcare Logistics segment for LSU and to the Specialized Transportation segment for Boyle, Skelton USA, and Skelton.

Of the goodwill acquired through the business combinations, \$4,850 (2021 - \$nil) is deductible for tax purposes.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

6. Trade and other receivables

	December 31, 2022	December 31, 2021
Trade receivables	\$ 99,232	\$ 90,739
Trade receivables due from related parties (note 21)	47	108
Impairment loss	(856)	(754)
Trade and other receivables	\$ 98,423	\$ 90,093

Estimates are used in determining the impairment loss related to trade receivables. These estimates are based on management's best assessment of the ECL of the related receivable balance, which involves estimates around the cash flows that are expected to be received. There is no impairment loss recorded against trade receivables due from related parties.

7. Inventories

Inventories consist of:

	December 31, 2022	December 31, 2021
Packaging inventory	\$ 1,558	\$ 936
Thermal packaging products and parts	909	546
Transportation equipment parts and supplies	859	849
Inventories	\$ 3,326	\$ 2,331

In 2022, the Company purchased a total of \$22,660 in inventory (2021 - \$8,876) and \$22,182 was recognized as an expense (2021 - \$7,773) during the year and included in direct operating expenses.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

8. Property, plant and equipment

Reconciliation of the net carrying amounts for each class of property, plant and equipment is summarized below:

	Facilities ¹	Furniture and fixtures	Leasehold improvements	Logistics and transportation equipment ¹	Total
Cost					
Balance at December 31, 2020	\$ 125,355	\$ 8,092	\$ 18,353	\$ 96,936	\$ 248,736
Additions	26,144	331	866	14,260	41,601
Additions through business combinations (note 5)	8,449	236	2,184	43,141	54,010
Dispositions	(4,233)	-	-	(496)	(4,729)
Foreign currency adjustments	140	5	30	473	648
Balance at December 31, 2021	155,855	8,664	21,433	154,314	340,266
Additions	2,744	511	1,518	33,013	37,786
Additions through business combinations (note 5)	2,756	-	672	1,731	5,159
Dispositions	-	(7)	(29)	(2,631)	(2,667)
Foreign currency adjustments	391	18	101	1,695	2,205
Balance at December 31, 2022	\$ 161,746	\$ 9,186	\$ 23,695	\$ 188,122	\$ 382,749
Accumulated depreciation					
Balance at December 31, 2020	\$ 53,871	\$ 6,363	\$ 9,209	\$ 60,378	\$ 129,821
Depreciation for the year	15,527	406	2,148	17,487	35,568
Dispositions	(2,886)	-	-	(341)	(3,227)
Foreign currency adjustments	-	-	-	(8)	(8)
Balance at December 31, 2021	66,512	6,769	11,357	77,516	162,154
Depreciation for the year	17,492	411	2,437	25,013	45,353
Dispositions	-	(3)	-	(991)	(994)
Foreign currency adjustments	42	1	6	307	356
Balance at December 31, 2022	\$ 84,046	\$ 7,178	\$ 13,800	\$ 101,845	\$ 206,869
Net carrying amounts					
At December 31, 2021	\$ 89,343	\$ 1,895	\$ 10,076	\$ 76,798	\$ 178,112
At December 31, 2022	\$ 77,700	\$ 2,008	\$ 9,895	\$ 86,277	\$ 175,880

¹ Facilities and certain logistics and transportation equipment assets are ROU assets, capitalized in accordance with IFRS 16. Refer to note 18.

The Company has applied judgement in estimating the useful life of property, plant and equipment and to determine the lease terms for ROU lease contracts that include renewal options. The assessment of whether the Company is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and ROU assets recognized. In applying such judgement, management relies on historical experience and other factors, including the current economic environment, which management believes is reasonable under the circumstances.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

9. Goodwill and intangible assets

	Goodwill	Customer relationships	Brand	Software	Total
Cost					
Balance at December 31, 2020	\$ 25,866	\$ 29,848	\$ -	\$ 6,026	\$ 61,740
Additions	-	-	-	1,642	1,642
Additions through business combinations (note 5)	148,524	115,218	37,297	-	301,039
Foreign currency adjustments	2,347	2,188	653	-	5,188
Balance at December 31, 2021	176,737	147,254	37,950	7,668	369,609
Additions	-	-	-	2,212	2,212
Additions through business combinations (note 5) ¹	9,836	12,700	3,200	-	25,736
Foreign currency adjustments	6,335	6,115	1,827	-	14,277
Balance at December 31, 2022	\$ 192,908	\$ 166,069	\$ 42,977	\$ 9,880	\$ 411,834
Accumulated amortization					
Balance at December 31, 2020	\$ -	\$ 22,910	\$ -	\$ 4,351	\$ 27,261
Amortization for the year	-	5,283	1,376	489	7,148
Balance at December 31, 2021	-	28,193	1,376	4,840	34,409
Amortization for the year	-	14,495	4,127	477	19,099
Foreign currency adjustments	-	484	144	-	628
Balance at December 31, 2022	\$ -	\$ 43,172	\$ 5,647	\$ 5,317	\$ 54,136
Net carrying amounts					
At December 31, 2021	\$ 176,737	\$ 119,061	\$ 36,574	\$ 2,828	\$ 335,200
At December 31, 2022	\$ 192,908	\$ 122,897	\$ 37,330	\$ 4,563	\$ 357,698

¹ Acquisition of LSU net of measurement period adjustments to goodwill recorded during the year.

The Company performs annual goodwill impairment testing. The Company assesses goodwill at the operating segment level, which is the lowest level within the Company at which goodwill is monitored for internal management purposes. The table below sets out goodwill allocated to operating segments:

Operating segment/reportable segment	December 31, 2022	December 31, 2021
Healthcare Logistics	\$ 31,872	\$ 19,720
Specialized Transportation	161,036	157,017
Total goodwill	\$ 192,908	\$ 176,737

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

9. Goodwill and intangible assets (continued)

The results of the annual impairment testing determined that the recoverable amounts of each of the Healthcare Logistics operating segment and the Specialized Transportation segment exceeded their respective carrying amounts. The recoverable amount of the Company's operating segments was determined using the value in use methodology, which involves discounting estimated future cash flows. Management believes that discounting estimated future cash flows results in a reasonable valuation for each segment. In assessing value in use, the estimated future cash flows have been discounted to their present values using pre-tax discount rates of 8.6% (2021 – 12.1%) for the Healthcare Logistics segment and 10.3% (2021 – 13.1%) for the Specialized Transportation segment, which approximate the Company's weighted average cost of capital for each segment; and expected growth rates for the healthcare sector of between 3.0% and 5.0%. Management has determined that no impairment has arisen in connection with the CGUs that gave rise to goodwill through the business combinations. Accordingly, no impairment loss has been recognized in each of the years ended December 31, 2022 and 2021.

During the year ended December 31, 2022, the Company acquired LSU in which its customer relationships and its brand comprised significant value to AHG. In aggregate, \$12,700 was attributed to the customer relationships and \$3,200 was attributed to the brand of LSU. Management considers these identifiable intangible assets to have finite useful lives which are amortized on a straight-line basis over ten years (note 5).

During the year ended December 31, 2021, the Company made acquisitions in which customer relationships and the brands of the acquired companies comprised significant value to AHG. In aggregate, \$115,218 was attributed to the customer relationships and \$37,297 was attributed to the brands of Boyle, Skelton USA, and Skelton. Management considers these identifiable intangible assets to have finite useful lives which are amortized on a straight-line basis over ten years (note 5).

The Company performs an assessment for indicators of impairment for customer relationships, brands and software at each reporting period. If an indicator of impairment exists, the Company would perform an impairment test to determine the recoverable amount. No such indicators of impairment were identified at any of the reporting periods covered by these financial statements.

10. Accounts payable and accrued liabilities

	December 31, 2022	December 31, 2021
Trade payables and accrued liabilities	\$ 41,194	\$ 36,935
Trade payables due to related parties (note 21)	587	652
Deferred revenue (note 16)	1,137	1,817
Accounts payable and accrued liabilities	\$ 42,918	\$ 39,404

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

11. Credit facilities

	December 31, 2022	December 31, 2021
Revolving credit facility	\$ -	\$ 11,000
Term facility	50,000	50,000
	50,000	61,000
Less: capitalized financing costs	(443)	(712)
Credit facilities	\$ 49,557	\$ 60,288

Recorded in the consolidated balance sheets as follows:

	December 31, 2022	December 31, 2021
Revolving credit facility	\$ -	\$ 11,000
Term facility	49,557	49,288
Credit facilities	\$ 49,557	\$ 60,288

The movement in credit facilities is as follows:

	December 31, 2022	December 31, 2021
Opening balance	\$ 60,288	\$ 24,667
Changes from financing cash flows		
Issuance of borrowings – revolving credit facility	12,000	50,000
Issuance of borrowings – term facility	-	25,000
	72,288	99,667
Less: capitalized financing costs	-	(621)
	72,288	99,046
Repayment of revolving credit facility	(23,000)	(39,000)
	49,288	60,046
Non-cash movements		
Amortization of capitalized financing costs	269	242
Ending balance	\$ 49,557	\$ 60,288

The Company is party to credit facilities with a syndicate of lenders. On February 19, 2021, in connection with the anticipated acquisitions of Skelton and Skelton USA, the credit facilities were amended to increase the amounts available to be drawn under the revolving credit facility and the term facility each by \$25,000. The amended credit facilities comprise a revolving credit facility in the aggregate principal amount of up to \$100,000 and a term facility in the aggregate principal amount of up to \$50,000. The remaining terms and conditions of the credit facilities were unchanged, except that they will mature and be due and payable on March 1, 2025. There is no repayment schedule for either the revolving credit facility or the term facility, except at maturity; however, the Company classifies the revolving credit facility in current liabilities because of its intention to reduce drawn amounts with cash flow from operations within twelve months. Financing costs of \$621, which apply to the credit facilities in aggregate, were capitalized in the term facility in connection with the amendment.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

11. Credit facilities (continued)

The credit facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans, and letters of credit, in each case, plus the applicable margin in effect from time to time. At December 31, 2022, the credit facilities comprise bankers' acceptances drawn at an interest rate of 5.9% (December 31, 2021 – 1.9%).

The credit facilities are guaranteed by each of the Company's material subsidiaries and are secured by (i) a first priority lien over all personal property of the Company, subject to certain exclusions and permitted liens, (ii) charges over certain material leased real property interests, and (iii) a first ranking pledge of 100% of the securities of any subsidiary owned by the Company.

The credit facilities are subject to customary negative covenants and include financial covenants requiring the Company to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested on a quarterly basis. At December 31, 2022, the Company was in compliance with all of its covenants under the credit facilities.

Amounts recognized in the consolidated statements of income and comprehensive income in connection with interest expense on the credit facilities for the year ended December 31, 2022 was \$2,001 (2021 – \$1,381).

12. Financial instruments and financial risk management

Accounting classifications and fair values

The Company's financial instruments consist of cash and cash equivalents, trade and other receivables, long-term deposits and other, accounts payable and accrued liabilities and its credit facilities (refer to note 11). The Company believes that the carrying amount of each of these items is a reasonable approximation of fair value given the short-term nature of the financial instruments.

As the credit facilities bear interest at a floating rate subject to fluctuations in the bank prime rate the carrying value of the debt approximates fair value.

Financial risk factors

The Company, through its financial assets and liabilities, has exposure to the following risks from its use of financial instruments: credit risk, liquidity risk, interest rate risk, and currency risk. Senior management monitors risk levels and reviews risk management activities as they determine to be necessary.

Credit risk

The Company is exposed to credit risk in the event of non-performance by counterparties in connection with its financial assets, namely cash and cash equivalents, trade and other receivables and long-term deposits. The Company does not typically obtain collateral or other security to support the trade and other receivables subject to credit risk but mitigates this risk by performing credit check procedures for new customers and monitoring credit limits for existing customers. Thereby, the Company deals only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance.

The maximum exposure to credit risk for cash and cash equivalents, trade and other receivables and long-term deposits approximate the amount recorded on the consolidated balance sheets.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

12. Financial instruments and financial risk management (continued)

Credit risk (continued)

Trade and other receivables aging is set out below:

	December 31, 2022	December 31, 2021
Current (not past due)	\$ 70,547	\$ 59,742
0-30 days past due	20,218	21,213
31-60 days past due	3,039	4,476
More than 61 days past due	1,008	2,232
Gross	94,812	87,663
Unbilled revenue	4,467	3,184
Impairment loss (note 6)	(856)	(754)
Trade and other receivables, net	\$ 98,423	\$ 90,093

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company's exposure to liquidity risk is dependent on the collection of trade and other receivables, or raising of funds to meet commitments and sustain operations. The Company controls liquidity risk by management of working capital, cash flows and the availability of borrowing facilities.

As of December 31, 2022, \$nil (2021 - \$11,000) has been drawn on the \$100,000 revolving credit facility, and \$50,000 (2021 - \$50,000) has been drawn on the \$50,000 term facility. There is no repayment schedule for the term facility except at maturity. The credit facilities are repayable in full on March 1, 2025.

The Company's accounts payable and accrued liabilities are due and payable in the short-term.

Interest rate risk

The Company has a revolving and term credit facilities that bear interest at a floating rate subject to fluctuations in the bank prime rate. Changes in the bank prime lending rate can cause fluctuations in interest payments and cash flows. The Company does not use derivative financial instruments to mitigate the effect of this risk. The facilities under this agreement are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. At December 31, 2022, the credit facilities comprises bankers' acceptances drawn at an interest rate of 5.9% (2021 - 1.9%).

During the year, interest rates have increased as the Governing Council of the Bank of Canada continues to target 2-3% inflation. However, there has been no significant impact on the Company's financial condition or results of operations as a result of such increases in interest rates.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

12. Financial instruments and financial risk management (continued)

Currency risk

The Company enters into foreign currency purchase and sale transactions and has assets and liabilities that are denominated in foreign currencies and thus are exposed to the financial risk of earnings fluctuations arising from changes in foreign exchange rates and the degree of volatility of these rates. The Company uses derivative instruments to reduce its exposure to foreign currency risk on an exceptional basis, such as in connection with the Boyle Transportation acquisition detailed in note 5.

Excluding its foreign subsidiaries, the Company has the following US dollar foreign currency denominated balances at December 31, 2022 and 2021:

Currency risk	December 31,	December 31,
	2022	2021
Cash	\$ 16,409	\$ 8,575
Trade and other receivables	15,489	12,461
Accounts payable and accrued liabilities	4,542	3,023

13. Share capital

The Company is authorized to issue an unlimited number of subordinate voting common shares, an unlimited number of multiple voting common shares, and an unlimited number of preferred shares, issuable in series. The subordinate voting shares and multiple voting shares rank *pari passu* with respect to the payment of dividends, return of capital and distribution of assets in the event of liquidation, dissolution, or wind-up. Holders of multiple voting shares are entitled to four votes per multiple voting share, and holders of subordinate voting shares are entitled to one vote per subordinate voting share on all matters upon which holders of shares are entitled to vote.

On December 12, 2022 the Company's parent, AMG, sold 1.76 million multiple voting shares (which converted to subordinate voting shares at the time of the sale by AMG), representing approximately 9.64% of the issued and outstanding subordinate voting shares, pursuant to a number of private agreements at a price of \$49.25 per subordinate voting share for an aggregate purchase price of \$86,680. There were no transaction costs incurred in connection with these private agreements.

Transaction costs of \$63, net of deferred taxes, have been offset against subordinate voting shares in connection with the acquisition made during the year ended December 31, 2022 (note 5).

On October 26, 2021 the Company, together with AMG, completed a new issue from treasury of 2.0 million subordinate voting shares and secondary offering of 1.5 million multiple voting shares (which converted to subordinate voting shares at the time of the sale by AMG), on a bought deal basis, at a purchase price of \$48.20 per subordinate voting share for aggregate gross proceeds of \$96,400 to the Company and \$72,300 to AMG. The proceeds of the treasury offering were used to pay the cash portion of the purchase price payable in connection with the acquisitions of Boyle and Skelton USA. Please refer to the Company's short form prospectus dated October 19, 2021.

Transaction costs of \$3,181, net of deferred taxes, were incurred in connection with the new issue and have been offset against the proceeds of the subordinate voting shares. Transaction costs of \$104, net of deferred taxes, have been offset against subordinate voting shares in connection with acquisitions made during the year ended December 31, 2021 (note 5).

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

13. Share capital (continued)

As of December 31, 2022, all of the multiple voting shares and 10,200 subordinate voting shares are owned by AMG. The following table summarizes the number of common shares issued:

	Number of common shares (in thousands)			Share capital (in thousands of dollars)		
	Multiple voting common shares	Subordinate voting common shares	Total common shares	Multiple voting common shares	Subordinate voting common shares	Total share capital
Balance at December 31, 2021	23,600	18,069	41,669	\$ 354,000	\$ 365,936	\$ 719,936
Shares issued in connection with business combination (note 5)	-	155	155	-	7,500	7,500
Transaction costs, net of tax	-	-	-	-	(63)	(63)
Shares issued in connection with the exercise of options	-	90	90	-	462	462
Shares converted in connection with secondary sale by AMG	(1,760)	1,760	-	(26,400)	26,400	-
Balance at December 31, 2022	21,840	20,074	41,914	\$ 327,600	\$ 400,235	\$ 727,835
Balance at December 31, 2020	25,100	12,503	37,603	\$ 376,500	\$ 173,162	\$ 549,662
Shares issued in connection with business combination (note 5)	-	1,799	1,799	-	75,166	75,166
Shares issued in connection with the secondary offering	-	2,000	2,000	-	96,400	96,400
Shares converted in connection with the secondary offering	(1,500)	1,500	-	(22,500)	22,500	-
Transaction costs, net of tax	-	-	-	-	(3,285)	(3,285)
Shares issued in connection with the exercise of options (note 15)	-	267	267	-	1,993	1,993
Balance at December 31, 2021	23,600	18,069	41,669	\$ 354,000	\$ 365,936	\$ 719,936

Dividends to subordinate voting and multiple voting shareholders

During the year ended December 31, 2022, the Company declared total dividends of \$10,883, or \$0.26 per common share (December 31, 2021 – \$7,854, or \$0.20 per common share), on subordinate voting and multiple voting shares. Included in accounts payable and accrued liabilities as at December 31, 2022 is \$2,934, or \$0.07 per common share (December 31, 2021 – \$2,083, or \$0.05 per common share) for dividends paid on January 16, 2023 and January 17, 2022, to common shareholders of record on December 31, 2022 and 2021 respectively.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

14. Earnings per share

Basic earnings per share

The basic earnings per share and the weighted average number of common shares outstanding have been calculated as follows:

(in thousands of dollars and number of shares)	December 31, 2022	December 31, 2021
Net income	\$ 76,275	\$ 89,954
Weighted average number of common shares	41,813	39,036
Earnings per share – basic	\$ 1.82	\$ 2.30

Diluted earnings per share

The basic earnings per share and the weighted average number of common shares outstanding after adjustment for the effects of all dilutive common shares have been calculated as follows:

(in thousands of dollars and number of shares)	December 31, 2022	December 31, 2021
Net income	\$ 76,275	\$ 89,954
Weighted average number of common shares	41,813	39,036
Dilutive effects:		
Stock options	812	928
Deferred share units	46	29
Weighted average number of diluted common shares	42,671	39,993
Earnings per share – diluted	\$ 1.79	\$ 2.25

15. Share-based payment arrangements

Stock option plan (equity settled)

The Company offers a stock option plan for the benefit of certain of its employees. Each stock option entitles its holder to receive one subordinate voting common share upon exercise. The exercise price payable for each option is determined by the Board of Directors at the date of grant. The options vest in equal installments over four years and the expense is recognized following the treasury method as each installment is fair valued separately and recorded over the respective vesting periods.

On December 11, 2019 the Board of Directors approved a grant of 1.65 million options, of which 128 thousand options were exercised during the year ended December 31, 2022 (December 31, 2021 – 373 thousand). Of the options outstanding at December 31, 2022, a total of 635 thousand (December 31, 2021 – 667 thousand) are held by non-executive directors; 200 thousand (December 31, 2021 – 225 thousand) are held by executive officers; with the remaining 239 thousand (December 31, 2021 – 310 thousand) held by management personnel. During the year ended December 31, 2022, nil (December 31, 2021 – 69 thousand) options were forfeited due to employee retirements.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

15. Share-based payment arrangements (continued)

Stock option plan (equity-settled) (continued)

Estimating fair value for share-based payment arrangements requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. The Company is also required to determine the most appropriate inputs to the valuation model, including estimates and assumptions with respect to expected life, risk-free interest rate, volatility, distribution yield, and forfeiture rate.

The fair value of the stock options granted was estimated using the Black-Scholes option pricing model using the following weighted average assumptions:

	December 11, 2019
Exercise price	\$ 15.00
Average expected option life	7 years
Risk-free interest rate	1.59%
Expected stock price volatility	24.77%
Average dividend yield	1.33%
Weighted average fair value per option of options granted	\$ 3.60

The table below summarizes the changes in the outstanding stock options:

(in thousands of options and in dollars)	<u>December 31, 2022</u>		<u>December 31, 2021</u>	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Opening balance	1,202	\$ 15.00	1,644	\$ 15.00
Exercised	(128)	15.00	(373)	15.00
Forfeited	-	-	(69)	15.00
Ending balance	1,074	\$ 15.00	1,202	\$ 15.00
Options exercisable	780	\$ 15.00	615	\$ 15.00

The Company recognized compensation expense of \$669 for the year ended December 31, 2022 (2021 – \$1,232), with corresponding increases to contributed surplus in connection with the vesting of options issued at the time of the initial public offering.

During the year ended December 31, 2022, 128 thousand options were exercised on a cashless basis resulting in 90 thousand subordinate voting common shares being issued from treasury and in the surrender of 38 thousand options used to fund the cashless option exercise. The volume weighted average price used to calculate the cashless exercises in accordance with the Company's Omnibus Equity Incentive Plan ranged between \$46.80 and \$54.97 per share at the time of exercises resulting in a \$462 increase in share capital. When options are exercised, the option value that was originally recognized is transferred from contributed surplus to share capital. The transfer of the option value of the options exercised resulted in a \$462 reduction to contributed surplus at \$3.60 per share.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

15. Share-based payment arrangements (continued)

Director deferred share units (“DSUs”) program (equity settled)

Each non-executive director receives at least 50% of their annual director retainer in DSUs. DSUs vest when granted but are not redeemable for settlement until the director ceases to be a member of the Board. The number of DSUs issued is calculated for each director as the director’s quarterly retainer divided by the volume weighted average trading price on the TSX for the five trading days prior to such issuance. For the year ended December 31, 2022, the Company recognized a compensation expense of \$632, with corresponding increases to contributed surplus (2021 – \$629).

The table below summarizes the changes in the outstanding DSUs:

(thousands of DSUs)	December 31, 2022	December 31, 2021
Opening balance	37	23
Granted	14	14
Closing balance	51	37

16. Revenue

a) **Revenue streams**

The Company generates revenue primarily from the provision of supply chain transportation and logistics services to its customers. The Company’s contracts are typically satisfied over a short period of time. Consequently, the Company applies the practical expedient and does not disclose information related to its remaining performance obligations.

b) **Disaggregation of revenue from contracts with customers**

In the following table, revenue from contracts with customers is disaggregated by major products and service lines. The table also includes a reconciliation of the disaggregated revenue with the Company’s reportable segments (note 4), and revenue disaggregated by primary geographical markets. All of the revenue generated in the United States comprises ground transportation revenue.

Major products/service lines	December 31, 2022	December 31, 2021
Logistics and distribution	\$ 155,575	\$ 115,255
Packaging solutions	21,290	20,072
Healthcare Logistics segment	176,865	135,327
Ground transportation	422,236	261,870
Air freight forwarding	34,383	29,214
Dedicated and last mile delivery	66,896	52,260
Intersegment revenue	(51,957)	(38,556)
Specialized Transportation segment	471,558	304,788
Total revenue	\$ 648,423	\$ 440,115

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

16. Revenue (continued)

b) **Disaggregation of revenue from contracts with customers (continued)**

Primary geographical markets	December 31, 2022	December 31, 2021
Canada	\$ 516,845	\$ 421,114
United States	131,578	19,001
Total revenue	\$ 648,423	\$ 440,115

c) **Deferred revenue**

One of the Company's specialized transportation operating segments bills customers for transportation services based on the pick-up date. When shipments remain in transit at the end of a period, the Company defers revenue until the shipments are delivered. The Company does not regularly bill customers in advance for logistics and distribution services. Consequently, fluctuations in deferred revenue will occur year over year and will depend on specifically negotiated payment terms resulting from customer billing requests or concerns related to credit risk. To date, the changes in deferred revenue have been largely insignificant. As at December 31, 2022 there was \$1,137 (2021 – \$1,817) recorded in accounts payable and accrued liabilities (note 10). Revenue recognized in 2022 of \$1,817 (2021 – \$914) was included in the opening deferred revenue balance at the beginning of the period.

17. Income taxes

a) **Amounts recognized in income or loss**

	December 31, 2022	December 31, 2021
Current income tax expense:		
Current taxes on income for the reporting year	\$ 29,855	\$ 21,117
Current taxes relating to previous years and other adjustments	(327)	264
	29,528	21,381
Deferred income tax recovery:		
Recognition of tax benefits related to loss for the year	(629)	(850)
Origination and reversal of temporary differences	(1,797)	3,302
Impact of change in tax rates of subsidiaries	-	6
Deferred taxes relating to previous years and other adjustments	358	(153)
Deductible temporary differences not recognized	23	(5,200)
	(2,045)	(2,895)
Income tax expense reported to the statements of income and comprehensive income	\$ 27,483	\$ 18,486

Total cash outflow for actual taxes paid for the year ended December 31, 2022 was \$30,989 (2021 – \$16,583).

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

17. Income taxes (continued)

b) **Amounts recognized directly in equity**

	December 31, 2022	December 31, 2021
Transaction costs, before tax	\$ 86	\$ 4,469
Tax	(23)	(1,184)
Transaction costs, net of tax	\$ 63	\$ 3,285

c) **Reconciliation of effective tax rate**

	December 31, 2022	December 31, 2021
Income before income taxes	\$ 103,758	\$ 108,440
Consolidated Canadian federal and provincial income tax rate	26.5%	26.5%
Income tax expense based on statutory rate	27,496	28,737
Increase (decrease) in income taxes resulting from non-deductible (non-taxable) items or other adjustments	256	379
Gain on step acquisition of equity-accounted investee	-	(10,050)
Share of profit of equity-accounted investee reported	-	(654)
Impact of varying statutory tax rates of subsidiaries	(322)	(189)
Deductible temporary differences not recognized	23	152
Taxes relating to previous years and other adjustments	30	111
Total income tax expense	\$ 27,483	\$ 18,486

d) **Deferred taxes**

	December 31, 2022	December 31, 2021
Deferred tax assets	\$ 5,809	\$ 7,832
Deferred tax liabilities	(48,609)	(50,430)
Net deferred tax liability	\$ (42,800)	\$ (42,598)

e) **Movement in deferred tax balances**

	December 31, 2022	Recognized in equity	Recognized in income or loss	Acquired in business combina- tions (note 5) ¹	Foreign currency adjustments	December 31, 2021
Plant and equipment	\$ (13,803)	\$ -	\$ (797)	\$ (116)	\$ (498)	\$ (12,392)
Accounts payable and accrued liabilities	819	-	207	-	5	607
Intangibles	(39,047)	-	3,742	(125)	(1,678)	(40,986)
Benefit of losses carried forward	2,783	-	629	-	-	2,154
Leases	4,194	-	(696)	61	81	4,748
Transaction costs	2,254	23	(1,040)	-	-	3,271
Net deferred tax (liability) asset	\$ (42,800)	\$ 23	\$ 2,045	\$ (180)	\$ (2,090)	\$ (42,598)

¹ Acquisition of LSU net of measurement period adjustments recorded during the year.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

17. Income taxes (continued)

e) **Movement in deferred tax balances (continued)**

	December 31, 2021	Recognized in equity	Recognized in income or loss	Acquired in business combina- tions	Foreign currency adjustments	December 31, 2020
Plant and equipment	\$ (12,392)	\$ -	\$ 1,370	\$ (12,534)	\$ (176)	\$ (1,052)
Accounts payable and accrued liabilities	607	-	154	-	-	453
Intangibles	(40,986)	-	1,849	(40,984)	(766)	(1,085)
Benefit of losses carried forward	2,154	237	614	-	-	1,303
Leases	4,748	-	(358)	3,580	42	1,484
Transaction costs	3,271	947	(734)	-	-	3,058
Net deferred tax asset (liability)	\$ (42,598)	\$ 1,184	\$ 2,895	\$ (49,938)	\$ (900)	\$ 4,161

f) **Unrecognized deferred tax liabilities**

As at December 31, 2022, temporary differences of \$40,390 (December 31, 2021 – \$40,390) exist in connection with wholly-owned investments in subsidiaries; and the related potential deferred tax liability of \$5,352 (December 31, 2021 – \$5,352) has not been recognized. The Company controls the dividend policies of its subsidiaries and controls the timing of payment of such dividends. Accordingly, the Company controls the timing of reversal of the related taxable temporary differences; and management is satisfied that they will not reverse in the foreseeable future.

g) **Non-capital loss carryforwards**

The Company recognized deferred tax assets in connection with certain losses for the current year on the basis that it will have sufficient future taxable profit.

The Company has total non-capital tax loss carry forwards of \$10,496 that begin to expire in 2039.

h) **Uncertainty over income tax treatments**

The calculation of current and deferred income taxes requires management to make certain judgements regarding the tax rules in jurisdictions where the Company performs activities. The Company believes that its accruals for tax liabilities are adequate for all open tax years based on its assessment of many factors, including interpretations of tax law and prior experience.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

18. Leases

The Company leases buildings and equipment in the operation of its Transportation and Logistics businesses. The Company is required to estimate the incremental borrowing rates used to discount lease liabilities if the interest rate implicit in the lease is not readily determined. The Company estimates its incremental borrowing rates for portfolios of leases with similar characteristics, such as similar risk profiles, same or similar types of security, and similar lease terms. Building lease terms range from 5 to 10 years. Facilities lease liabilities are calculated using the Company's incremental borrowing rate based on the specific lease commitments and term for each facility. The average incremental borrowing rate for facilities for the year ended December 31, 2022 is 5.20% (2021 – 3.71%). Equipment lease terms range from 1 to 7 years. Equipment lease liabilities are calculated using the operating segment's average incremental borrowing rate on an equipment lease portfolio basis for that period. The average incremental borrowing rate for equipment for the year ended December 31, 2022 is 4.87% for Specialized Transportation and 5.49% for Healthcare Logistics (2021 – 3.13% for Specialized Transportation; 2.66% for Healthcare Logistics).

Right-of-use assets – Facilities	As at and for the year ended December 31, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 89,343	\$ 71,484
Add: additions	2,744	26,144
Add: additions through business combinations	2,756	8,449
Less: derecognition	-	(1,347)
Less: depreciation	(17,487)	(15,527)
Foreign currency adjustments	345	140
Ending balance	\$ 77,701	\$ 89,343
Right-of-use assets – Logistics and transportation equipment	As at and for the year ended December 31, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 33,443	\$ 27,256
Add: additions	9,294	7,431
Add: additions through business combinations	1,042	9,349
Less: depreciation	(11,519)	(10,622)
Foreign currency adjustments	73	29
Ending balance	\$ 32,333	\$ 33,443
Net carrying amounts of right-of-use assets included in property, plant and equipment	December 31, 2022	December 31, 2021
Facilities	\$ 77,701	\$ 89,343
Logistics and transportation equipment	32,333	33,443
Balance	\$ 110,034	\$ 122,786

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

18. Leases (continued)

Lease liabilities – Facilities	As at and for year ended December 31, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 98,681	\$ 77,676
Add: additions	2,744	26,144
Add: additions through business combinations	2,006	8,475
Add: interest expense	3,623	3,700
Less: principal repayments	(16,857)	(13,756)
Less: interest payments	(3,623)	(3,700)
Foreign currency adjustments	351	142
Ending balance	\$ 86,925	\$ 98,681

Lease liabilities – Logistics and transportation equipment	As at and for the year ended December 31, 2022	As at and for the year ended December 31, 2021
Opening balance	\$ 28,282	\$ 27,270
Add: additions	9,294	7,431
Add: additions through business combinations	1,392	4,918
Add: interest expense	1,165	1,138
Less: principal repayments	(12,177)	(11,353)
Less: interest payments	(1,165)	(1,138)
Foreign currency adjustments	13	16
Ending balance	\$ 26,804	\$ 28,282

Cash lease principal payments	Year ended December 31, 2022	Year ended December 31, 2021
Repayments of lease principal	\$ (29,034)	\$ (25,109)
Total lease payments	\$ (29,034)	\$ (25,109)

Lease liabilities	December 31, 2022	December 31, 2021
Facilities	\$ (86,925)	\$ (98,681)
Logistics and transportation equipment	(26,804)	(28,282)
Balance	\$ (113,729)	\$ (126,963)

Lease liabilities included in consolidated balance sheets	December 31, 2022	December 31, 2021
Current	\$ (26,547)	\$ (26,446)
Non-current	(87,182)	(100,517)
Balance	\$ (113,729)	\$ (126,963)

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

18. Leases (continued)

Maturity analysis for lease liabilities – contractual undiscounted cash flows	December 31, 2022	December 31, 2021
Less than one year	\$ 30,523	\$ 30,839
One to 5 years	81,317	86,694
More than 5 years	12,886	23,360
Total undiscounted lease liabilities	\$ 124,726	\$ 140,893

Amounts recognized in the consolidated statements of income and comprehensive income in connection with interest expense for lease liabilities for year ended December 31, 2022 was \$4,788 (2021 – \$4,838). Total cash outflow for leases for the year ended December 31, 2022 was \$33,822 (2021 – \$29,947).

Net investment lease	As at and for the year ended December 31, 2022	As at and for year ended December 31, 2021
Opening balance	\$ 784	\$ -
Add: additions	-	1,489
Add: interest received	11	29
Less: payments received	(723)	(705)
Less: interest income	(11)	(29)
Ending balance	\$ 61	\$ 784

In January 2021, the Company sub-leased a facility to a third party that had previously been classified as a right-of-use asset. The Company derecognized net book value of \$1,347 from right-of-use assets and established a net investment lease of \$1,489 resulting in a net gain of \$142 included in other income in connection with this facility. As at December 31, 2022 the current portion of \$61 (2021 – \$723) in connection with this net investment lease is included in trade and other receivables. The long-term portion of \$nil (2021 – \$61) is recorded in long-term deposits and other. The Company recognized \$11 of interest income for year ended December 31, 2022 (2021 – \$29).

The table below sets out the current and long-term portions of the net investment lease:

Maturity analysis for net investment lease receivable – contractual undiscounted cash flows	December 31, 2022	December 31, 2021
Less than one year	\$ 61	\$ 734
One to 5 years	-	61
More than 5 years	-	-
Total undiscounted net investment lease receivable	\$ 61	\$ 795

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

19. Interest expense

Interest expense recognized in income and comprehensive income	December 31, 2022	December 31, 2021
Leases	\$ 4,788	\$ 4,838
Credit facilities	2,001	1,381
Other	69	-
Total interest expense	\$ 6,858	\$ 6,219

Interest expense recognized in the consolidated statements of income and comprehensive income equates to total interest paid for the years ended December 31, 2022 and 2021.

20. Commitments and contingencies

- a) The Company is, from time to time, involved in claims, legal proceedings and complaints arising in the normal course of business and provisions for such claims have been recorded where appropriate. The Company does not believe the final determination of these claims will have an adverse material effect on its consolidated financial statements.
- b) As at December 31, 2022, the Company had outstanding letters of guarantee in the amount of \$365 (2021 – \$365).
- c) The Company has made commitments to lease fleet equipment, with the terms to begin upon delivery of the equipment in 2023. Commitments range from 72 to 84 months and total \$11,371 (2021 – \$8,512).
- d) The Company has made commitments to purchase fleet equipment totalling approximately \$10,126 (2021 – \$7,820).

21. Related parties

During the year, the Company entered into transactions with related parties that were incurred in the normal course of business. The Company's policy is to conduct all transactions and settle all balances with related parties on market terms and conditions. All outstanding balances with these related parties are to be settled in cash within two months of the reporting date. None of the balances are secured. No expense has been recognized in the current year or prior year for bad or doubtful debts in respect of amounts owed by related parties.

The Company is indirectly controlled by Michael Andlauer, the Chief Executive Officer and CODM. Included in these consolidated financial statements are the following transactions and balances with companies related either directly or indirectly to Mr. Andlauer.

The Company recovers certain facilities lease costs from Andlauer Management Group Inc. ("AMG"). The Company also provides certain shared services (primarily accounting services) to AMG.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

21. Related parties (continued)

AHG acquired a 49% interest in Skelton USA on March 1, 2021 (note 5) which wholly owns Skelton Truck Lines, Inc. (“SKINC”). SKINC provides specialized 2-8°C transportation services to Skelton Canada Inc. in the United States, and Skelton Canada Inc. provides specialized 2-8°C transportation services to SKINC in Canada. On November 1, 2021, AHG acquired the remaining 51% of Skelton USA. Accordingly, transactions with SKINC have not been included in related party transactions in the tables below for the year ended December 31, 2022, but have been included for the period from March 1, 2021 to October 31, 2021.

Andlauer Properties and Leasing Inc. (“APLI”) is a subsidiary of AMG and leases certain facilities and logistics and transportation equipment to the Company. The Company also leases facilities and logistics and transportation equipment from arm’s length providers. The Company provides certain shared services (primarily accounting services) to APLI.

9143-5271 (“9143”) Quebec Inc. is a subsidiary of AMG and leases a facility in Quebec to the Company. The Company provides certain shared services (primarily accounting services) to 9143.

Ready Staffing Solutions Inc., a company owned by Mr. Andlauer’s spouse, provides the Company with temporary agency employee services – providing hourly dock labour for handling operations, principally in the GTA. The Company also purchases temporary agency employee services from arm’s length providers.

1708998 Ontario Limited (Medical Courier Services) (“MCS”) is a subsidiary owned 80% by AMG and provides transportation services to the Company, providing extended reach for shipments where the Company does not have facilities or equipment. The Company also provides certain shared services (primarily accounting services) to MCS.

Med Express is a subsidiary owned 50% by AMG and provides transportation services to the Company, providing extended reach for shipments where the Company does not have facilities or equipment.

D.C. Racking & Maintenance Inc. (“DCR”) and Logiserv Inc. (“Logiserv”) are partially owned by Cameron Joyce, a member of AHG’s board of directors. DCR provides warehouse racking installation and maintenance and repair services to the Company. Logiserv provides warehouse racking and racking components as well as warehouse racking installation, maintenance and repair services. The Company also purchases warehouse racking installation, maintenance and repairs, and warehouse racking and racking components from arm’s length providers.

C-GHBS Inc. is a subsidiary of AMG and provides air travel services to the Company.

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

21. Related parties (continued)

	December 31, 2022	December 31, 2021
Revenue		
Transportation services		
1708998 Ontario Limited (Medical Courier Services)	\$ 173	\$ 360
Skelton Truck Lines, Inc.	-	1,180
Shared service recovery		
Andlauer Properties and Leasing Inc.	20	19
Andlauer Management Group Inc.	13	66
9143-5271 Quebec Inc.	32	31
1708998 Ontario Limited (Medical Courier Services)	13	14
Expenses		
Transportation services		
1708998 Ontario Limited (Medical Courier Services)	147	188
Med Express Ltd.	40	12
Skelton Truck Lines, Inc.	-	319
Contract labour services		
Ready Staffing Solutions Inc.	6,517	4,918
Equipment rent		
Andlauer Properties and Leasing Inc.	2,301	2,261
Facility rent		
Andlauer Properties and Leasing Inc.	2,163	1,771
9143-5271 Quebec Inc.	1,532	1,532
Maintenance services		
D.C. Racking and Maintenance Inc. and Logiserv Inc.	54	29
Travel services		
C-GHBS Inc.	104	67
Capital Expenditures		
Purchases of logistics and transportation equipment		
Logiserv Inc.	47	20

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

21. Related parties (continued)

	December 31, 2022	December 31, 2021
Trade receivables due from related parties		
Andlauer Properties and Leasing Inc.	\$ 15	\$ 74
Med Express Ltd.	-	2
1708998 Ontario Limited (Medical Courier Services)	32	32
	47	108
Due from related parties		
Andlauer Management Group Inc.	56	16
Former T.F. Boyle Transportation shareholders	-	92
	56	108
Total due from related parties	\$ 103	\$ 216
Trade payables due to related parties		
Ready Staffing Solutions Inc.	\$ 463	\$ 343
1708998 Ontario Limited (Medical Courier Services)	18	-
Andlauer Properties and Leasing Inc.	73	302
Andlauer Management Group Inc.	9	-
C-GHBS Inc.	12	-
Logiserv Inc.	12	7
	587	652
Due to related parties		
Andlauer Properties and Leasing Inc.	342	254
Former Skelton Canada Inc. shareholders	-	1,032
	342	1,286
Total due to related parties	\$ 929	\$ 1,938

Key management personnel

The Company's key management personnel, and persons connected with them, are also considered to be related parties for disclosure purposes. Key management personnel are defined as those individuals having authority and responsibility for planning, directing and controlling the activities of the Company and include the Company's CEO, four named executive officers comprising key management and the Board of Directors.

Key management personnel compensation comprised the following:

	December 31, 2022	December 31, 2021
Key management compensation		
Salaries and benefits	\$ 3,498	\$ 3,212
Share-based payment arrangements	426	784
Director deferred share units	632	629
Total key management compensation	\$ 4,556	\$ 4,625

Andlauer Healthcare Group Inc.
Notes to Consolidated Financial Statements
For the years ended December 31, 2022 and 2021

(In thousands of Canadian dollars, except shares, share price and earnings per share)

22. Capital management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital, as well as the level of dividends and distributions to ordinary shareholders.

The Board of Directors seeks to maintain a balance between the higher returns that might be possible with higher levels of borrowing and the advantages and security afforded by a sound capital position. The Company monitors capital using a net leverage ratio, calculated as net debt divided by the last twelve months' earnings before interest, taxes, depreciation and amortization ("EBITDA"). The Company seeks to keep its net leverage ratio below 3.0 in the ordinary course of business.

	December 31, 2022	December 31, 2021
Revolving credit facility	\$ -	\$ 11,000
Total lease liabilities	113,729	126,963
Term facility	49,557	49,288
Less: cash and cash equivalents	(65,855)	(24,990)
Net debt	97,431	162,261
Net income	76,275	89,954
Interest income	(599)	(198)
Interest expense	6,858	6,219
Income tax expense	27,483	18,486
Depreciation and amortization	64,452	42,716
EBITDA	174,469	157,177
Net leverage ratio	0.56	1.03

23. Government assistance

The Government of Canada introduced the Canada Emergency Wage Subsidy ("CEWS") as part of its COVID-19 pandemic response. The program was effective from March 2020 to October 2021 and provided a wage subsidy for entities that experienced revenue declines over the comparable period in the prior year. During the year ended December 31, 2021, the Company recorded a \$1,209 reduction to direct operating expenses in connection with the CEWS for its Nova Pack Ltd. subsidiary.

SHAREHOLDER INFORMATION

Shares Outstanding (As at March 2, 2023)

Total Subordinate Voting Shares ("SVS"): 20,074,253

Total Multiple Voting Shares: 21,840,000

Stock Exchange Listing

Andlauer Healthcare Group's SVS are listed on the Toronto Stock Exchange under the symbol "AND"

Investor Contacts

Peter Bromley

Chief Financial Officer

T: 416-744-4916

E: Investor.relations@andlauer.ca

Bruce Wigle

Investor Relations

T: 647-496-7856

E: Investor.relations@andlauer.ca

Registrar and Transfer Agent

TSX Trust Company

Auditor

KPMG LLP

Legal Counsel

Goodmans LLP

Virtual Annual General Meeting

Thursday, May 4, 2023, at 10 a.m. (ET)

www.andlauerhealthcare.com

EXECUTIVE TEAM



Michael Andlauer
Chief Executive Officer



Peter Bromley, CPA, CA
Chief Financial Officer



Stephen Barr
President, Transportation



Bob Brogan
President, Specialty Solutions



Dean Berg
President, Logistics

BOARD OF DIRECTORS



Peter Jelley
Chair



Rona Ambrose^{1,2,3}
Lead Director



Michael Andlauer
Director and Chief Executive Officer



Andrew Clark^{1,2}
Director



Cameron Joyce
Director



Joseph Schlett, CPA, CA¹
Director



Evelyn Sutherland, FCPA, FCA^{1,2*,3}
Director



Thomas Wellner^{1,3*}
Director

¹ Independent director

² Member of Compensation, Nominating & Governance Committee

³ Member of the Audit Committee

* Denotes Committee Chair





PLATFORM OF COMPANIES



100 Vaughan Valley Blvd. • Vaughan, Ontario • L4H 3C5
www.andlauerhealthcare.com